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Summary 
Schistosoma mansoni is one of the causative agents of schistosomiasis, which is a 
neglected tropical disease with great importance to public health in Africa, Asia and 
South America. It is estimated that about 249 million people are infected with this 
disease and another 732 million are at risk of infection. Praziquantel is the only 
available drug to treat schistosomiasis, and several mass-treatments have been 
performed with the same drug. However, in the last years, the number of reported 
cases of resistance to Praziquantel has been increasing and there is concern about 
the future of the schistosomiasis treatment. Therefore, it is very important to study the 
phenomenon of resistance to uncover the genetic mechanisms involved and its 
associated characteristics. Nevertheless, since the resistant strains previously studied 
were obtained from patients, it is not possible to guarantee that certain characteristics 
are, in fact, related to drug resistance, due to lack of an isogenic strain for comparison. 
Given this limitation, within the ambit of this project, it was developed a Praziquantel-
resistant strain of S. mansoni, which is isogenic to its susceptible parental strain, 
except for the resistance determinants.  
Efflux pumps are often indicated as being involved in chemotherapy failures by other 
drugs. Therefore, in this study, we tested the hypothesis of the involvement of efflux 
pumps in Praziquantel-resistant phenotype in S. mansoni. For that, an Ethidium 
Bromide accumulation assay was performed in the presence of an efflux pumps 
inhibitor (Verapamil), as well as a susceptibility assay with several Praziquantel 
concentrations in the presence or absence of the same inhibitor, and a qRT-PCR to 
determine the expression levels of the gene SmMDR2. Comparing the results obtained 
for each strain, we found that resistant males have a higher efflux pump activity, as 
well as a lower susceptibility to the drug and an increased expression of the target 
gene. 
In this thesis, the presence of morphological differences between the two strains was 
also assessed. With the use of scanning electron microscopy, males and females from 
both susceptible and resistant strains were examined in the presence and absence of 
Praziquantel. We found significant tegumental damages in the susceptible strain 
exposed to the drug, but not in the resistant strain. Moreover, optical microscopy of the 
eggs demonstrated that those released by resistant strain worms are significantly 
Summary 
XXVI 
 
smaller than those of susceptible strain. The use of mass spectrometry allowed the 
determination of the proteome of males and females from both strains under drug 
exposure or not. This permitted to characterize the proteome of each strain and to 
identify 60 different proteins, some of which differentially expressed between the 
different groups. 
Thus, taking advantage of the development of a new model for the study of 
Praziquantel-resistance in S. mansoni, it was possible to determine some differences 
between the two strains, which possibly are associated with Praziquantel-resistance in 
S. mansoni. Namely, this study strongly suggests the involvement of efflux pumps in 
Praziquantel-resistance in S. mansoni, and more research is needed to assess the 
possibility of applying combined therapies with efflux pumps inhibitors to increase 
worm susceptibility to the Praziquantel-treatment. In addition, the morphological 
changes observed are a very important finding, because these changes may be occur 
in vivo and have impact in the resistant parasite biology, and consequently on 
disease's transmission and pathology, namely in a neuroschistosomiasis scenario. 
Moreover, the elucidation of the proteome of both strains will be important for future 
works, representing a significant progress in the study of Praziquantel-resistance in S. 
mansoni. 
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Sumário 
Schistosoma mansoni é um dos agentes causadores de schistosomose, uma doença 
tropical negligenciada com grande importância para a saúde pública em África, Ásia e 
na América do Sul. Estima-se que cerca de 249 milhões de pessoas se encontrem 
infetadas com esta doença e outros 732 milhões estejam em risco de infeção. 
Praziquantel é o fármaco disponível para o tratamento da schistosomose, e vários têm 
sido os tratamentos em massa realizados com este mesmo medicamento. Porém, nos 
últimos anos, o número de casos reportados de resistência ao Praziquantel tem vindo 
a aumentar, existindo uma grande preocupação sobre o futuro do tratamento da 
schistosomose. Por isso mesmo, é fundamental estudar este fenómeno de resistência, 
tentando descobrir os mecanismos genéticos envolvidos e as características 
associadas. Contudo, uma vez que as estirpes resistentes que têm sido estudadas 
foram obtidas através de colheitas em pacientes, não é possível garantir que 
determinadas características estejam, de facto, relacionadas com a resistência ao 
fármaco, devido à falta de uma estirpe suscetível isogénica para comparação. Tendo 
em conta esta limitação, no âmbito deste projeto foi desenvolvida uma estirpe de S. 
mansoni resistente ao Praziquantel, que é isogénica à linha parental suscetível que 
lhe deu origem, exceto no que respeita aos determinantes associados à resistência.  
As bombas de efluxo são muitas vezes apontadas como estando envolvidas em falhas 
de tratamento com outros fármacos. Neste trabalho foi testada a hipótese do 
envolvimento de bombas de efluxo na resistência ao Praziquantel em S. mansoni, 
através de ensaios de acumulação de Brometo de Etídio na presença de um inibidor 
de bombas de efluxo (Verapamil), assim como ensaios de suscetibilidade com várias 
concentrações de fármaco na presença e ausência deste inibidor, e, ainda a 
realização de qRT-PCR para determinação dos níveis de expressão do gene 
SmMDR2. Comparando os resultados obtidos para cada uma das estirpes, verificou-
se que os machos da estirpe resistente apresentam uma maior atividade de bombas 
de efluxo, uma menor suscetibilidade ao fármaco e uma maior expressão do gene 
estudado.  
Nesta tese também foram estudadas eventuais diferenças morfológicas entre ambas 
as estirpes. Com recurso a microscopia eletrónica de varrimento, foram observados 
machos e fêmeas das estirpes suscetível e resistente, na presença e ausência de 
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Praziquantel. Foi possível constatar a existência de danos significativos no tegumento 
da estirpe suscetível exposta ao fármaco, o que não aconteceu na estirpe resistente. 
Além disso, os ovos de ambas as estirpes foram observados por microscopia ótica e 
constatou-se que os ovos da estirpe resistente são significativamente mais pequenos. 
O recurso a espectrometria de massa permitiu ainda o estudo do proteoma de machos 
e fêmeas de ambas as estirpes, sob a ação do fármaco ou não. Este ensaio permitiu 
caracterizar o proteoma de cada uma das estirpes e identificar 60 proteínas diferentes, 
algumas das quais expressas de forma diferente entre os grupos. 
Assim, tirando partido do desenvolvimento de um novo modelo para o estudo da 
resistência ao Praziquantel em S. mansoni foi possível determinar algumas diferenças 
existentes entre ambas as estirpes, que possivelmente estarão associadas à 
resistência ao Praziquantel em S. mansoni. Nomeadamente, este trabalho sugere 
fortemente o envolvimento de bombas de efluxo na resistência ao Praziquantel em S. 
mansoni, sendo necessários mais estudos para avaliar a possibilidade da aplicação 
de terapias combinadas com inibidores de bombas de efluxo para aumentar a 
suscetibilidade dos vermes ao tratamento com Praziquantel. As alterações 
morfológicas observadas são um achado muito importante, pois poderão ocorrer in 
vivo e ter reflexos na biologia do parasita resistente, com impacte na transmissão e 
patologia da doença, nomeadamente num cenário de neuroschistosomose. Além 
disso, a elucidação do proteoma de ambas as estirpes será fundamental para 
trabalhos futuros, representando um grande progresso para o estudo da resistência 
ao Praziquantel em S. mansoni.
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1. The parasite Schistosoma 
The genus Schistosoma belongs to the Phylum Platyhelminthes, Class Trematoda, 
Subclass Digenea, Order Schistosomatida and Family Schistosomatidae [1]. This 
genus comprehends six different species, namely, Schistosoma haematobium, 
Schistosoma japonicum, Schistosoma mansoni, Schistosoma mekongi, Schistosoma 
guineensis and Schistosoma intercalatum, all of them causing schistosomiasis. There 
are two major forms of schistosomiasis – intestinal and urogenital (Table I-1) [2-5]. 
Table I-1. Parasite species, forms of schistosomiasis caused for these and respective 
geographical distribution.  
 Species Geographical distribution 
Intestinal  
schistosomiasis 
Schistosoma mansoni 
Africa, Middle East, Caribbean, Brazil, 
Venezuela and Suriname 
Schistosoma japonicum China, Indonesia, Philippines 
Schistosoma mekongi 
Several districts of Cambodia and  
Lao People’s Democratic Republic 
Schistosoma guineensis 
Schistosoma intercalatum 
Rain forest areas of central Africa 
Urogenital  
schistosomiasis 
Schistosoma haematobium Africa, Middle East, Corsica (France) 
Based on updated and corrected data from: (http://www.who.int/mediacentre/factsheets/fs115/en/ - last 
accession on February 5th 2016). 
Schistosoma spp. comprehends several life stages, namely eggs, miracidium, 
sporocyst, cercariae, schistosomula and adult worms. The adult schistosomes present 
a cylindrical body with a complex tegument, as well as two terminal suckers (oral and 
ventral) (Figure I-1). They are white or grayish worms with about 7 to 20 mm [2, 4, 5], 
and can live in their mammalian host 3 to 10 years but, in some cases, can survive as 
long as 40 years [4]. Unlike other trematodes, schistosomes have sexual dimorphism 
(Figure I-1). Adult male and female worms live much of the time in copula within the 
perivesical (S. haematobium) or mesenteric (all the other species) venous plexus, with 
the female fixed into the gynaecophoric canal of the male (Figure I-1), where she 
produces eggs and he fertilizes them. The egg production is dependent on fatty acid 
oxidation, being those acids obtained from the host [6]. Besides fatty acids, the glucose 
necessary to get energy from glucose metabolism is also derived from the host by 
erythrocytes digestion [7]. Schistosomes have a blind digestive tract, thus they cannot 
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excrete waste products, regurgitating them into the bloodstream. Most of the expelled 
products are useful for blood-based and urine-based diagnostic assays [4]. 
 
Figure I-1. Paired adult worms of schistosome, showing a female into the gynaecophoric canal 
of the male, and the oral and ventral suckers of the adult worms, from [8]. 
The life cycle of Schistosoma spp. is shown in Figure I-2. As said above, the adult male 
and female worms live within the veins of their mammalian host, where they mate and 
produce fertilized eggs. The females produce hundreds (African species - S. mansoni, 
S. haematobium, S. intercalatum and S. guineensis) to thousands (oriental species - 
S. japonicum and S. mekongi) of eggs per day. The Schistosoma spp. eggs enclose a 
ciliated larva called miracidium that produces proteolytic enzymes, essential for the 
eggs migration to the lumen of the bladder (S. haematobium) or the intestine (all the 
other species). The eggs are excreted in the urine or feces of the host, and they can 
stay viable for up to 7 days [2, 4, 5]. Sometimes inflammation can occur in certain 
tissues of the host, due to the deposition of eggs in these locations, rather than being 
excreted. On the other hand, the eggs that reach freshwater will hatch, releasing 
miracidium that then infect a suitable snail host (for example Biomphalaria glabrata for 
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S. mansoni). In its intermediate host, the parasite undergoes asexual replication 
through mother and daughter sporocyst stages, eventually shedding tens of thousands 
of cercariae (the infectious form for the mammalian host) into the water. This part of 
the life cycle in snails requires 4 to 6 weeks before the release of cercariae. Once 
cercariae penetrate the skin of the mammalian host, the maturing larvae called 
schistosomula need about 5 to 7 weeks before becoming adults and producing eggs. 
These periods in both the intermediate and in definitive hosts, during which the 
infection is ongoing but release of cercariae from snails or eggs from mammals cannot 
be detected, are denominated pre-patent periods. Contrarily to what happens to eggs, 
that die 1 to 2 weeks after female worm release them, cercariae can only stay infective 
in freshwater during 1 to 3 days, even though they deplete the most of their energy 
reserves in a few hours [2, 4 ,5]. 
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Figure I-2. Transmission cycle of the three main species of Schistosoma: S. haematobium, S. 
mansoni and S. japonicum. A: Paired adult worms (male holding female). B: Eggs (left to right, S. 
haematobium, S. mansoni, S. japonicum). C: Ciliated miracidium. D: Intermediate host snails (left to 
right, Oncomelania, Biomphalaria, Bulinus). E: Cercariae. From [4], image adapted from [2]. 
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Transmission invariably occurs when people and other mammals suffering from 
schistosomiasis contaminate freshwater with their excreta containing parasite eggs, 
which hatch in freshwater. People become infected when infectious cercariae 
penetrate the skin during contact with freshwater, usually by swimming or washing [9]. 
Schistosoma japonicum and S. mekongi schistosomiasis are zoonosis that, besides 
humans, also infect a broad range of mammalian hosts, as dogs, pigs, or cattle, greatly 
complicating the control and elimination efforts. Rodents and non-human primates can 
also be infected by S. mansoni and S. haematobium, but they are not the predominant 
reservoir of this specie. To successfully control and eliminate human schistosomiasis, 
it is very important to have a good knowledge about the life cycle and the transition of 
the parasite between intermediate and definitive hosts [2, 4, 5]. 
2. History of schistosomiasis 
The earliest description of schistosomiasis can be found in the ancient Assyro-
Babylonian literature, namely in the Papyrus Ebers of Egypt [10], where it is mentioned 
a worm disease that seems to be related with urinary bleeding (possibly a S. 
haematobium infection). However, any systematic effort was performed to understand 
the basic life cycle and pathogenesis of this disease until the XIX century [8].  
The first description of Schistosoma spp. is attributed to Theodor Bilharz, who during 
the autopsy of a young man found worms in the portal vein [11]. This German 
pathologist also described the presence of eggs with a spine, which indicates that he 
could be in presence of S. mansoni or S. haematobium, but makes impossible the 
distinction of those two species, since this is a common characteristic (Figure I-2). 
Those findings were communicated to his professor von Freholdtz in 1851, and two 
years later presented in a meeting at Breslau. Bilharz also described the characteristic 
pathologic changes and clinical features of schistosomiasis, and named those worms 
Distomium haematobium [12, 13]. In 1858, Wienland and Cobbold disagreed with this 
nomination because of the observation that only one of the two suckers of these worms 
led into the oral cavity, and suggested the name Schistosoma [14, 15], where “Schisto” 
describes the slit in the male and “soma” the body of the enveloped female worm. 
Therefore, since 1864 the official nomenclature to this disease is "schistosomiasis", 
but in Europe and the Middle East the term “bilharzia” has been commonly used [8]. 
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3. Schistosomiasis  
Schistosomiasis or bilharzia is one of the major parasitic diseases of the tropics [2, 4, 
5]. As said in section 1 of this Chapter, this disease is caused by several species of 
Schistosoma - trematode parasites, also known as blood-dwelling fluke worms [16]. 
There are three main species infecting human beings, namely, S. haematobium, S. 
mansoni, and S. japonicum. Schistosoma haematobium and S. mansoni both occur in 
Africa and the Middle East, whereas only S. mansoni is present in the Americas. 
Schistosoma japonicum is localized in Asia, primarily the Philippines and China. The 
other three species, S. mekongi, S. guineensis, and S. intercalatum are more locally 
distributed, the first one in the Mekong River basin and the other two in West and 
Central Africa (Figure I-3), and they also cause human disease. Each of those species 
has specificity to its suitable snail host, which makes their distribution be defined by 
their host snails’ habitat range [4].  
With over 249 million individuals infected with schistosomiasis worldwide, more than 
97% are in sub-Saharan Africa (Figure I-4). About 120 million of all people infected 
have symptoms and 20 million have severe consequences. This parasitosis causes 
about 280 000 deaths annually and around 732 million people are at risk of infection 
in 78 countries [17-19]. 
 
Figure I-3. Global distribution of human schistosomiasis transmission. From [3], modified from 
[2, 17]. 
I – General introduction 
9 
 
 
Figure I-4. Worldwide distribution of schistosomiasis, taking into account the prevalence rate, 
from [20]. 
In Europe, schistosomiasis occurs due to the arrival of infected immigrants, and 
schistosomiasis in returning travelers is one of the most common imported tropical 
infections with potentially serious acute and long-term complications [5, 21]. In 11 
years (1997-2008), more than 400 cases of travel-associated schistosomiasis were 
reported by the Geosentinel Surveillance Network in 27 sites from 12 Western 
countries [22]. Most cases of imported schistosomiasis in Europe are described in 
travelers returning from sub-Saharan Africa [22], and only rare cases are still imported 
from Asia and Latin America, possibly due to the reduced incidence in those continents 
as a result of successful schistosomiasis control programs, most notably in China [5, 
21]. 
3.1. Clinical presentation 
As described in [5], schistosomiasis presentation can be divided into several 
syndromes: 
1) Asymptomatic/non-specific are the cases where some patients can only report low 
grade fever, dermatitis or pruritic rash (commonly called “swimmers itch”) at the site of 
infection after cercariae penetrating the skin. It is very important identifying these 
patients at an initial stage of infection, because an early diagnosis can prevent long-
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term complications [23]; 2) Acute schistosomiasis is an immune complex-mediated 
response to the immature forms of the parasite migrating through the body, and it 
presents fever, malaise, urticarial, wheeze, hepatosplenomegaly and eosinophilia, 
usually appearing 4 to 8 weeks after parasite exposure; 3) Hematuria is very common 
in patients infected by S. haematobium. As this species is responsible for urogenital 
schistosomiasis, gynecological presentations with vulva schistosomiasis [24] or 
hematospermia or lumpy semen may also occur. Those situations have a slightly 
increased risk of HIV transmission; 4) Diarrhea can occur in patients with 
schistosomiasis, but this disease rarely cause chronic diarrhea. Patients with a 
combination of diarrhea and eosinophilia should immediately be questioned about 
tropical travel; 5) Chronic infection is a very serious situation where patients can 
present permanent scarring of the bladder, liver and urogenital system, due to eggs 
retained in those tissues. In the most severe situations with heavy chronic infections 
the risk of bladder carcinoma (S. haematobium), or liver scarring and/or portal 
hypertension with ascites (S. mansoni or S. japonicum) is increased; 6) 
Neuroschistosomiasis occurs with the egg deposition in the central nervous system, 
namely in brain or spinal cord, and this is a very rare but important syndrome [5]. 
Neuroschistosomiasis should be seen as a severe condition where the prognosis is 
mainly dependent on an early treatment, and consequently on an early diagnostic [3, 
25-29]. This syndrome is probably under-recognized, because besides rare by 
comparison with intestinal or urogenital cases, it is not uncommon. Schistosoma 
mansoni, S. haematobium and S. japonicum are responsible for almost all reported 
cases of neuroschistosomiasis [3, 29, 30], with S. mansoni and S. haematobium 
usually associated to the spinal cord, and S. japonicum to encephalic disease [3, 27-
29]. In most symptomatic patients, the occurrence of nerve damage depends on the 
presence of parasite eggs in the nervous tissue and on the host immune response [3, 
29].  
3.2. Diagnosis 
Except for acute schistosomiasis, the finding by microscopy of S. haematobium eggs 
on filtered urine and eggs from all other species on stool, is the gold standard for 
diagnosis of schistosomiasis. However, in light infections and in travelers from endemic 
countries, this method has low sensitivity. Therefore, serology for schistosome 
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antigens is the standard screening method in these situations, which has a sensitivity 
of over 90% [5]. 
An important step on schistosomiasis diagnosis is the knowledge of patient historical. 
Suspected individuals or travelers returning from endemic areas should be questioned 
about freshwater exposure, positive serological tests, and history of cercarial 
dermatitis. This might be indication of infection, but the absence of these indicators 
does not avoid the need of further investigations. So it is very important take in account 
in clinical practice that, neither a negative serological test nor the absence of eggs in 
urine or stool is sufficient to rule out schistosomiasis [3]. 
3.3. Treatment  
The standard treatment of schistosomiasis is with Praziquantel (PZQ), giving a dose 
of 40 or 60 mg/kg bodyweight orally. In heavy infection or for acute cases, the treatment 
may need to be repeated, as PZQ does not effectively treat immature schistosomes. 
In addition corticosteroids can also be given during acute phase to alleviate symptoms. 
Follow up of schistosomiasis patients is only advantageous if eggs or eosinophilia were 
found, in order to make sure the resolution within approximately 3 months. Antibody 
serology for schistosomiasis may remain positive for years following successful 
treatment, and therefore it is not useful for follow up. Most cases of schistosomiasis, 
once treated, will cause no long-term sequel, although there should be taken into 
account the investigation of patients with a history of schistosomiasis and hematuria 
with cystoscopy, due to the risk of bladder carcinoma in cases of prolonged S. 
haematobium infection [5]. Besides antischistosomal drugs, corticosteroids, and 
surgery are used to treat neuroschistosomiasis cases [26-28]. 
3.4. Disease control 
Vaccines and prophylactic treatment are not available to prevent infections with 
Schistosoma spp.. Thus, to prevent schistosomiasis transmission, it is essential apply 
effective treatment to infected people, prevent sewage contamination of freshwater, 
eliminate the intermediate host snails, and avoid human contact with water containing 
infected snails [4]. Besides, environmental changes can either increase or decrease 
transmission [31, 32]. Alterations not only in snail habitat, but also their predators, are 
determinant for transmission [33].   
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The advances in schistosomiasis control with the massive use of PZQ in endemic 
areas resulted in substantial decreases in morbidity and mortality of this disease, but 
were not sufficient to stop its geographical expansion, and schistosomiasis continues 
spreading to new regions [34, 35]. Environmental changes resulting from the 
industrialization of developing countries and migration of populations are thought to be 
behind the continued spread of the infection [31, 34, 36]. Moreover, the number of 
travel-related schistosomiasis reports has been increasing [37]. 
The outcomes of the schistosomiasis control programs are considered disappointing 
[38]. In fact, decades of mass PZQ administration have had negligible effects on the 
global prevalence of schistosomiasis. In certain regions, the disease has expanded to 
new foci [39]. Less than 5% of the schistosomiasis-affected population is treated with 
PZQ. With such this low coverage, it will be difficult for any program to make significant 
contributions to schistosomiasis control. Since PZQ does not prevent re-infection, drug 
administration needs to be constant in order to maintain disease control [40]. 
PZQ has been used so extensively and so exclusively [41], that it is important to have 
in mind that the trap of an excessive medicalization should be avoided. 
Schistosomiasis is a poverty disease, so its full control could be achieved, in principle, 
just by removing the socio-economic causes that lay at its basis. The often-
recommended integrated approach to control schistosomiasis should comprise, 
among other measures, sanitation, water supply, ecological interventions and health 
education. In the transmission of schistosomiasis, Man almost appears as a vector, 
because the transmission would be interrupted, at least in regions without non-human 
hosts, if people avoided urinating or defecating in or near water bodies [41]. 
In this context of poverty, the impossibility of alternative approaches as vaccination, 
and the difficulties in attack the snails populations acting as intermediate hosts, make 
chemotherapy the main approach for schistosomiasis control. In the last decades, 
several PZQ mass administration programs have been applied to millions of people 
every year, since this is the only available drug to treat this disease. This massive and 
exclusive use of this drug for so much time brought concerns about the rise of PZQ-
resistant schistosomes, and those concerns are on theory legitimated by what 
happened in the past with other anti-infective agents [41].  
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4. Praziquantel and resistance 
PZQ was developed in the 1970s and shortly referenced by the World Health 
Organization as the treatment of choice for schistosomiasis, and began to be marketed 
for human use as Biltricide [42].  PZQ is the generic name for 2-(cyclohexylcarbonyl)-
1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline-4-one, which is a white 
crystalline powder with a bitter taste, normally stable under normal storage conditions, 
practically insoluble in water but soluble in some organic solvents. The commercial 
preparations of the drug are usually racemic mixtures composed of equal portions of 
the “laevo” and “dextro” isomers, of which only the “laevo” form has schistosomicidal 
activity [42-44].  
PZQ is first metabolized during its passage through the liver and it disappears relatively 
rapid from the circulation with a half-life of 1-1.5 h, and the elimination from the body 
is rapid and mainly via urine, the remainder via feces, and is largely complete after 24 
h. Animal tests have demonstrated that PZQ has very low toxicity and no genotoxic 
risks were detected in assays for mutagenicity or carcinogenicity [42]. 
The mechanism of action is not exactly known at present, but experimental evidence 
indicates that PZQ kills adult worm schistosomes by increasing the Calcium 
permeability of the tegument membrane, thereby, disrupting Calcium homeostasis and 
causing paralysis of the worms [45]. PZQ is considered an excellent drug and has 
several advantages, mainly regarding safety, efficacy and cost, but the lack of efficacy 
against Schistosoma spp. immature forms is its potential significant limitation [41, 42].  
As said in section 3.4 of this Chapter, the massive programs performed raise concerns 
about PZQ-resistance in Schistosoma spp.. In fact there has already been some 
observed decrease of PZQ susceptibility in some strains [46]. Therefore, the research 
of new antischistosomal drugs is imperative and urgent. Although a large number of 
compounds have been tested for its potential activity against schistosomes (some of 
them seeming promising), until now there is not an alternative or adjunct compound to 
PZQ. The uncertain about the mechanisms of action of this drug is not favorable to the 
development of alternative drugs to treat schistosomiasis, and therefore it is also 
important to better characterize this drug and its mechanisms of action [41]. 
Resistance to PZQ is defined as the genetically transmitted loss of susceptibility in 
worm populations that were previously susceptible to PZQ. In this process, 
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chemotherapy selectively removes susceptible worm individuals from the genetically 
heterogeneous populations leading to an increase in individuals carrying genes 
conferring drug resistance that are passed to the offspring generation. Over several 
generations, resistance genes accumulate so that a large number of worms within a 
population survive following treatments. It is believed that the transmission of genetic 
material only occurs through parental lineages, as there is, as yet, no evidence for 
transposition of genetic components in this process [47].  
Research into the biochemical, genetic and proteomic mechanisms of drug resistance 
have been shown to be of great relevance for drug target identification and 
epidemiological studies [48]. The repetitive exposure to sub-lethal doses of PZQ in 
mice have generated resistant strains of S. mansoni in 2 generations [49], and field 
and laboratory isolates with reduced susceptibility or possible resistance to PZQ have 
already been identified [42-43, 50-56], thus demonstrating that resistance is more than 
a hypothetical possibility, though no gene(s) has been unequivocal associated with this 
phenotype. 
The less efficacy of PZQ treatment of schistosomiasis appeared about 10-15 years 
after the application of this treatment in a massive scale in Egypt and after the 
introduction of this disease in Senegal [46, 47, 57]. The longtime of exposure before 
appearance of resistance, suggests that PZQ resistance might be a multiple gene 
phenomenon [58]. In the both cases, the less susceptibility of worms obtained from 
uncured patients was also observed in mouse model [59], which may indicate that the 
PZQ failure is related to worms characteristics. But other factors as host factors, heavy 
worm burdens, and pre-patent infections may also be involved in the treatment failure 
[47, 59]. The difficulties verified in treat travelers with schistosomiasis further 
emphasize the need to remain vigilant [59]. So far, to our knowledge, no full and 
unequivocal association has been made between PZQ-resistance and a gene or a 
genetic trait.   
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5. Efflux pumps  
One of the more common mechanisms for development of drug resistance is through 
increased drug efflux, often mediated by multidrug transporters. Multidrug transporters 
are involved in multidrug resistance (MDR), which is a phenomenon where besides the 
resistance to a drug, there is an unexpected cross-resistance to several other 
compounds, even structurally unrelated [60]. Multidrug transporters are responsible for 
remove xenobiotics and toxic compounds, including drugs, from cells and tissues, and 
are considered to have low substrate specificity [61]. Furthermore, the efflux 
mechanisms are currently known to be the major components of resistance to many 
drugs, particularly to antibiotics. [62, 63]. There are certain efflux pumps (EPs) that 
extrude specific antibiotics, but there are those called multidrug EPs, that extrude a 
diversity of compounds with diverse functionality and structure [64]. An excellent 
approach used nowadays to deal with MDR is undoubtedly the use of inhibitors of EPs, 
thus improving the clinical performance of many drugs [65]. The Figure I-5 shows a list 
of some substrates and inhibitors commonly identified.  
Chemotherapy failure in the treatment of bacteria and cancer has been associated to 
the activity of ATP-binding cassette (ABC) transport proteins. The ABC-transport 
proteins belong to a family of membrane proteins that play important roles, such as 
transport of diverse compounds (peptides, hormones, cholesterol and iron), in both 
eukaryotes and prokaryotes [66, 67]. However, several members of this family of drug 
transporters, as P-glycoproteins (Pgp) (Figure I-5) and the multidrug resistance-
associated proteins (MRPs) in particular, might be involved in drug resistance in 
parasites [68-70]. PZQ may interact with Pgp or MRPs in a number of ways, as either 
a substrate or as an inhibitor of transport mediated by the ABC-transport proteins [71]. 
Most of the information regarding ABC-transporters and their involvement in MDR is 
based on studies of Pgp, an organic cation pump that is the product of ABCB1 gene. 
It is a full transporter comprised of 12 transmembrane segments divided into two 
transmembrane (TM) domains, each linked with an ATP-binding domain (Figure I-5) 
[72]. 
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Figure I-5. P-Glycoprotein (Pgp) structure and list of substrates and inhibitors, adapted from [72]. 
The activity of EPs of prokaryotes and eukaryotes can be inhibited with phenothiazines 
[73]. The mechanism by which phenothiazines affect EPs activity is by inhibiting 
ATPases [74]. Phenothiazines are known to reverse resistance of a number of human 
parasites [74]. Since phenothiazines inhibit EPs, resistance of parasites to antiparasitic 
drugs may, as it is the case of most micro-organisms, be due to an over-expression of 
EPs. Indeed, there are supporting evidences that drug resistance of helminths involves 
EPs [73-75]. 
Two homologues ABC-transport protein have been identified in S. mansoni: SmMDR1 
and SmMDR2. SmMDR1 has no known homologues, whereas SmMDR2 is 
homologous to mammalian Pgp (MDR1) [76]. There are indications that multidrug 
transporters may be involved in modulating levels of PZQ susceptibility in 
schistosomes [60]. PZQ is both an inhibitor and a substrate of recombinant SmMDR2 
[77], and chronic exposure of worms to sub-lethal concentrations of PZQ results in up-
regulation of SmMDR2 and SmMRP1, and changes the distribution of anti-Pgp 
immunoreactivity in the worm [78, 79]. Importantly, higher levels of schistosome 
SmMDR2 and SmMRP1 are associated with reduced PZQ susceptibility [78, 79]. 
Indeed, an Egyptian isolate with reduced PZQ susceptibility, expresses dramatically 
higher levels of SmMDR2 [78]. 
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6. Schistosome proteome 
Research of schistosome proteome might be extremely important for the 
understanding of immune mechanism, investigation of new diagnostic and vaccine 
candidates, as well as the development of new drugs [80]. 
The enlargement of schistosome databases alongside the upgrading of technology in 
this area, helped to improve the schistosome proteome studies. However, there is still 
limitations in finding much schistosome proteins that have high homology with proteins 
from other organisms, because there is no organisms so phylogenetically close to 
schistosome that has good protein sequences available in the public databases.   So 
the sequencing of schistosome transcriptome came greatly improve the level of 
identification in proteomics studies, as well as the reliability of protein identification 
associated with the orthologous proteins from public databases, because it was 
possible to generate large databases of Schistosoma coding sequences [81, 82]. 
The most proteomics studies in schistosome are done in order to compare the amount 
of proteins at different stages of the life cycle of the parasite, which may enable to 
identify proteins with specific functions in each stage of the life cycle. [83]. In a study 
done by Curwen and colleagues [84], they compared soluble extracts from three 
different stages of S. mansoni life cycle, and the most abundant proteins identified for 
them were characterized for having high immunogenicity and thus considered as good 
vaccine candidates. Analysis of protein extracts from various life stages of schistosome 
reveled proteins with specific stage functions, and these proteins were considered 
good candidates to be promising therapeutic targets [85]. 
Other proteomics studies in schistosome have discovered gender-specific proteins 
involved specifically in sexual maturation, in reproduction, and in hormone receptors. 
These proteins are considered of great importance in the disease control as they may 
be used to block egg laying, which may reduce pathology induced by eggs and also 
reduce the disease transmission [85, 86]. 
Proteomics analysis is considered a powerful tool to screen samples derived from 
pathogens and identify proteins that are possibly involved in pathogenesis [87]. In the 
case of schistosome studies, it is used to identify proteins from complex samples 
(tegument and secretion proteins) or to study differential expression of proteins [84, 
86, 88-91]. This approach has also been used to analyze protein expression in adult 
I – General introduction 
18 
 
schistosomes from susceptible, less susceptible or resistant hosts, helping to identify 
essential molecules involved in the survival and development of the parasite, and 
perhaps new vaccine candidates or even drug targets useful for the schistosomiasis 
control [87].  
7. Schistosome tegument 
In contrast to nematodes, schistosomes are covered by a living syncytium, called 
tegument (Figure I-6), instead of cuticle [92]. The schistosome tegument is delimited 
by an invaginated plasma membrane at its basal surface, while its apical surface has 
an unusual hepatalaminate appearance, which is considered the normal plasma 
membrane, covered by a membrane-like secretion, called membranocalyx (Figure I-6) 
[92]. 
 
Figure I-6. Illustrative representation of the schistosome tegument. Mc: Membranocalyx; Pm: 
Plasma membrane; P: Pits; DB: Discoid body; MLV: Multilaminate vesicle; Mt: Microtubule; S: Spine; 
BM: Basal membrane, adapted from [92]. 
One of the most important organ of schistosome parasites is the tegument, which has 
been immensely studied, once it plays a crucial role on the protection of the parasite 
against the action of immune system of the host, helping the adult worms to survive in 
the host, since it is renovated in just a few hours [93-96]. Other important roles of this 
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organ are related to its ability to absorb nutrients and molecules and synthesize some 
proteins [97-99].  
The advent of microscopy techniques used to analyze the worms’ structure, 
contributed to the knowledge of the importance of schistosome tegument, and also 
allowed distinguishing between male and female worms of Schistosoma spp., like the 
fact that males have more and larger thorns than females. Therefore the emergence 
of transmission electron microscopy and scanning electron microscopy (SEM) has 
revolutionizing the knowledge of the adult worms of schistosomes and the description 
of its sexual dimorphism [96]. 
As said before, schistosome adult parasites can live about 3 to 10 years in their 
definitive mammalian host, mostly due to their ability to escape the immune-mediated 
responses [100]. Some features of these parasites as the peculiar structure of their 
tegument and their capacity to penetrate the immune system, facilitate them to stay 
alive within the blood vessels environment for so long [101]. 
In addition to all the important features and functions already mentioned, the tegument 
helps the parasite interacting to the host, and also participates in the process of 
excretion, osmoregulation and signal transduction [102, 103]. This great organ plays 
another major role in helping the parasite at different stages of the life cycle, as 
assisting them to transform from the free-living stage (miracidium and cercariae) into 
the parasitic stage (schistosomula and adult worms), which allow the parasite to 
migrate through various environments in the mammalian host. Schistosome parasites 
can do these by switching the composition of their tegument in a short time. Indeed, 
this characteristic allows the parasite switch from an immune-sensitive to an immune-
refractory state [102, 104].   
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8. Background and research objectives 
In the last years we have developed in the laboratory at Instituto de Higiene e Medicina 
Tropical, Universidade Nova de Lisboa (IHMT/UNL) a S. mansoni PZQ-resistant strain 
(IHMT/UNL) in mice [56] derived from the PZQ-susceptible BH (Belo Horizonte, Minas 
Gerais, Brazil) S. mansoni parasite strain, placing us in an excellent position to perform 
direct comparisons between the PZQ-resistant and the parental PZQ-susceptible 
strains. The knowledge of possible mechanisms involved in resistance to PZQ will 
allow a better assessment of the epidemiology of drug-resistance to PZQ in the field 
also enabling a more effective decision of, for example, a potential drug to use in 
combination with PZQ. Having this in mind, the main objectives of this thesis are: 
1- Evaluate the role of EPs in S. mansoni PZQ-resistance phenotype, by 
comparing the EPs activity in the PZQ-susceptible and the PZQ-resistant parasite 
strains, upon exposure to a compound known to inhibit eukaryotic EPs – Verapamil 
(Chapter II); 
2- Develop a new methodology allowing the study, on a real time basis, of 
the transport of the universal efflux substrate Ethidium Bromide (EtBr) and to correlate 
the efflux inhibitory effects with the resistant variant (Chapter II); 
3- Evaluate morphological alterations in the S. mansoni PZQ-resistance 
phenotype by comparing the PZQ-resistant strain obtained under PZQ drug pressure 
with the PZQ-susceptible strain (Chapter III); 
4- Analyze the proteome of S. mansoni PZQ-resistant adult worms and 
compare it with its parental fully PZQ-susceptible strain, using a high throughput Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) identification (Chapter IV).   
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1. Abstract 
Schistosomiasis is a neglected disease caused by a trematode of the genus 
Schistosoma that is second only to malaria in public health significance in Africa. PZQ 
is the drug of choice to treat this disease due to its high cure rates and no significant 
side effects. However, in the last years increasingly cases of loss of sensitivity to PZQ 
have been reported, which has caused growing concerns regarding the emergence of 
resistance to this drug. Here we describe the selection of a parasitic strain that has a 
stable resistance phenotype to PZQ. It has been reported that drug resistance in 
helminths might involve EPs such as members of ABC-transport proteins, including 
Pgp and MRPs families. Here we evaluate the role of EPs in S. mansoni resistant to 
PZQ, by comparing the EPs activity in susceptible and resistant strains. The evaluation 
of the efflux activity was performed by an EtBr accumulation assay in presence and 
absence of Verapamil. The role of EPs in resistance to PZQ was further investigated 
comparing the response of susceptible and resistant parasites in the absence and 
presence of different doses of Verapamil, in an ex vivo assay, and these results were 
further reinforced through the comparison of the expression levels of SmMDR2 by 
qRT-PCR. This work strongly suggests the involvement of Pgp-like transporters 
SmMDR2 in PZQ drug resistance in S. mansoni. Low doses of Verapamil successfully 
reverted drug resistance. Our results give an indication that a combined therapy with 
PZQ and natural or synthetic Pgp modulators can be an effective strategy for the 
treatment of confirmed cases of resistance to PZQ in S. mansoni.  
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2. Introduction 
Schistosomiasis is a neglected tropical disease that affects approximately 249 million 
people worldwide, 97% of which are located on the African continent. It ranks, with 
malaria and tuberculosis, as a major source of morbidity despite strenuous control 
efforts [1, 2]. Furthermore, amongst all the parasitic diseases, schistosomiasis is one 
of the most common human parasitic diseases whose socioeconomic impact is only 
surpassed by malaria [2, 3]. Schistosomiasis is caused by blood flukes of the genus 
Schistosoma, which have a complex life cycle comprising a vertebrate host and an 
invertebrate host. Schistosoma mansoni is one of the species that infects humans [4–
6] and one of the most common etiological agent for human schistosomiasis, causing 
more than 83 million human infections in 54 countries [7]. 
Schistosomiasis treatment relies almost exclusively on the anthelmintic PZQ. However 
this drug does not prevent reinfection and, with large-scale control programs promoting 
the extensive use of PZQ for more than 20 years in some African nations, concern 
regarding the selection of drug resistant parasites has been raised [8–10]. 
Resistance to PZQ is defined as the genetically transmitted loss of susceptibility in 
worm populations that were previously susceptible to PZQ. In this process, 
chemotherapy selectively removes susceptible individuals from the genetically 
heterogeneous populations leading to an increase of individuals carrying genotypic 
determinants conferring drug resistance that are passed to the offspring. After several 
generations, a large number of worms within the population survive following treatment 
[10]. 
In vivo artificial selection in mice has previously produced PZQ-resistant lines of S. 
mansoni in only two generations after repeated exposure to sub-lethal doses of the 
drug [9], demonstrating that resistance is more than an hypothesis. Low cure rates in 
response to PZQ emerged 10–15 years ago after mass scale use in countries like 
Egypt and Senegal [11, 12]. Worms from the non-cured patients were repeatedly less 
susceptible to PZQ when tested in a mouse model [13]. Worm genetic determinants 
for resistance led to PZQ failure, although host factors, among other factors, were also 
considered to have contributed to PZQ failure such as heavy worm burdens and pre-
patent infections [10, 13]. Difficulties in obtaining cure among travelers with 
 II - The role of efflux pumps in S. mansoni Praziquantel resistant phenotype 
35 
 
schistosomiasis [13] further emphasized the need to maintain surveillance in order to 
avoid parasite spread to places where the intermediate host is present. 
Chemotherapy failures in bacteria and cancer treatments have been associated to the 
activity of ABC-transport proteins [12, 14]. ABC-transport proteins are a large family of 
membrane proteins that have many multiple cellular functions including the transport 
of diverse compounds such as peptides, hormones, cholesterol and iron [14, 15]. 
Several members of this family also transport drugs, such as the P-glycoprotein (Pgp, 
ABCB1) and the multidrug resistance-associated proteins (MRPs, ABCCs), both 
reported to be involved in drug resistance by exporting drugs to the outside of parasites 
either by increased efflux activity or genetic over expression. PZQ is hypothesized to 
interact with Pgp-like or MRPs either as an efflux substrate or as a competitor of 
transport mediated by the ABC-transport proteins of other efflux substrates [16]. It has 
been demonstrated that the activity of EPs of prokaryotes and eukaryotes can be 
inhibited by Calcium channel blockers, such as Phenothiazines or Verapamil as they 
inhibit the transporter associated ATPases, such as those that provide the energy for 
the activity of Pgp-like EPs [16–19]. 
ABC transporter cDNAs that have been characterized in schistosomes includes 
SmMDR2 [20], a S. mansoni orthologue of Pgp, and SmMRP1 [21], a S. mansoni 
orthologue of MRP1. SmMDR2 is expressed at higher levels in female parasites than 
in males [20, 22], while male express higher SmMRP1 levels than females [21]. 
Notably, adults of S. mansoni up regulate the expression of both of these transporters 
in response to PZQ. Furthermore, higher basal levels of both SmMDR2 and SmMRP1 
correlate with reduced PZQ susceptibility [21, 22], and PZQ inhibition activity, likely 
also a substrate of SmMDR2 [19]. Based on these findings, Kasinathan and colleagues 
have hypothesized that Schistosoma MDR transporters may be modulating the 
responsiveness of parasites to PZQ [18]. 
In this study, we have selected from the fully susceptible parasite BH strain, by 
stepwise drug pressure, a S. mansoni variant strain that is stably resistant to PZQ. This 
resistant parasite variant strain, obtained from infected mice, tolerates up to 1,200 mg 
PZQ/kg of mouse bodyweight and is isogenic to its parental fully susceptible 
counterpart, except for the genetic determinants accounting for the PZQ-resistant 
phenotype. This resistant parasitic strain enabled us to further test the hypothesis that 
EPs play an important role in the development of the PZQ-resistant phenotype in S. 
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mansoni. Therefore, the aim of this study was to evaluate the role of EPs in S. mansoni 
PZQ-resistant phenotype, by comparing the EPs activity in the PZQ-susceptible and 
the PZQ-resistant parasite strains, upon exposure to a compound known to inhibit 
eukaryotic EPs - Verapamil. A new methodology was also developed allowing the 
study, on a real time basis, of the transport of the universal efflux substrate EtBr and 
to correlate the efflux inhibitory effects with the resistant variant, which over-expresses 
Pgp-like EPs demonstrating their important role on PZQ-resistance in S. mansoni.  
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3.  Material and Methods 
3.1. Reagents 
The inhibitor Verapamil, EtBr and Calcium Chloride (CaCl2) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). PZQ was purchased from Merck & Co. 
(Kenilworth, NJ, USA) and dissolved in 1% of Dimethyl Sulfoxide (DMSO) from Sigma-
Aldrich, used for stock solutions, which were subsequently diluted to an appropriate 
concentration in culture media. All solutions were prepared in distilled, sterile water, on 
the day of the experiments. 
3.2. Animal model 
The PZQ-resistant parasitic strain of S. mansoni was developed using Mus musculus 
CD1 line males, approximately eight weeks old. CD1 is considered the animal model 
of choice for S. mansoni infection, because it is a good host for this parasite mimicking 
the S. mansoni human infection [23]. 
The mice used, weighting around 20 g, were obtained from the animal breeding facility 
(bioterium) of IHMT/UNL. They were kept in appropriate conditions of temperature 
(±21° C), humidity (45–55%) and light (12 h cycles of light/darkness). The infection 
occurred by exposing mice tails to about 100 cercariae of S. mansoni each, thus mice 
infection occurred by natural transdermal penetration of the cercariae. 
3.3. Parasite isolation 
In this study we used a S. mansoni BH line, susceptible to PZQ. This parasitic line is 
routinely kept in our group at IHMT/UNL, using B. glabrata as intermediate host. 
Our stable PZQ-resistant parasite strain was obtained from the BH line submitted to 
various steps of PZQ continuous drug pressure, starting with a sub therapeutic PZQ 
dose and finishing with 1,200 mg/kg of PZQ. Cioli and colleagues [13] demonstrated 
that in the murine model we can define a line of S. mansoni as resistant if it has a LD50 
greater than 100 mg/kg, therefore our variant strain resists to 12 times this value. 
Infected CD1 mice were checked approximately 60 days post parasite infection by 
Kato-Katz procedure. If eggs were found in feces, mice were then treated orally with 
PZQ solution at appropriate dose. If, on day 15, post PZQ treatment, viable eggs 
(verified by live miracidium inside the eggs and Kato-Katz procedure) continued to be 
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eliminated, mice were euthanized and eggs present in the liver were used to obtain 
miracidium to subsequently infect B. glabrata snails. Once B. glabrata snails start 
eliminating S. mansoni cercariae (30 to 60 days after snail infection), new CD1 mice 
were re-infected and the previous procedure was repeated, continuing the PZQ-
resistant strain selection in vivo (Figure II-1). PZQ dose was increased every two 
passages as shown in Figure II-2. 
 
Figure II-1. Selection of S. mansoni PZQ-resistant strain. This selection was carried out under 
continuous PZQ increased pressure using CD1 mice over several passages. 1 - Transcutaneous 
infection of mice with ~100 cercariae; 2 - Oral administration of PZQ after infection confirmation by the 
presence of eggs in the feces (±60 days post-infection - dpi); 3 - Mice were euthanized to collect adult 
worms and miracidium (eggs in the liver) (±75 dpi); 4 - B. glabrata snails were infected with miracidium 
released from eggs; 5 - Cercariae were released from snails (±45 dpi). 
doi:10.1371/journal.pone.0140147.g001. 
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Figure II-2. Schematic cartoon of PZQ doses during the selection procedure for the S. mansoni 
PZQ-resistant strain. The parasite from BH susceptible strain was submitted to various steps of PZQ 
pressure, and the dose was increased along the cycle number of passages.  
doi:10.1371/journal.pone.0140147.g002. 
Adult worms (8–10 weeks post-infection) were collected by liver-perfusion, as 
described by Lewis and colleagues [24], and maintained in saline solution for the EtBr 
efflux assay or in RPMI medium (Sigma-Aldrich) for the ex vivo PZQ susceptibility 
assays. 
3.4. Ethidium Bromide efflux assay 
EtBr efflux assay was performed with the objective of comparing the EPs activity 
between males of both PZQ-susceptible and PZQ-resistant parasite strains as 
described by Viveiros and colleagues, adapted in this study for the assessment of 
parasite efflux activity [25]. Verapamil (2.2 μM and 4.4 μM), known as an inhibitor of 
ABCB1 (Pgp) efflux pump activity was used as EtBr efflux inhibitor at concentrations 
that did not compromise viability. EtBr concentration was previously optimized for each 
strain of adult worms in order to determine the lowest concentration which reflects the 
balance between EtBr accumulation by influx (passive diffusion) and extrusion by 
active efflux during the 35 minutes of the assay (EtBr influx-efflux steady-state whose 
accumulation - fluorescent signal - inside the worms is above the lowest signal 
detectable by the fluorescence microscope). This ensures that the observed increase 
of accumulation of EtBr during the 35 minutes of the assay is due to inhibition of EPs 
that promotes increased accumulation of the fluorophore inside the worms [25]. To 
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measure the time-curve of increased EtBr accumulation promoted by the inhibitor 
Verapamil, our EtBr control group were worms incubated with the same concentration 
of EtBr in the absence of Verapamil. All experiments were carried out in triplicate with 
three worms each (n = 9). For quantification of fluorescence, three areas, of each 
worm, of the same size, of the worm central section (below the cecum ramification), as 
shown in Figure II-3, were defined and fluorescence intensity was measured and 
quantified using ImageJ software (imagej.nih.gov) and background intensity was 
subtracted. Thus, each time-point of relative fluorescence in each assay corresponds 
to the mean of EtBr fluorescence (n = 9) that remains accumulated per unit of time that 
we compare to the EtBr control group (no inhibitor) [25]. 
 
Figure II-3. Schematic representation of the worm areas analyzed by ImageJ. Fluorescence 
quantification was made in three defined regions, of the same size, corresponding to the worm central 
section (below the cecum ramification), of each worm and fluorescence intensity within each region was 
quantified using ImageJ software (imagej.nih.gov) and background intensity was subtracted.  
doi:10.1371/journal.pone.0140147.g003. 
After collecting parasites (as described before), they were separated by sex, and only 
males were used for this experiment since EtBr binds non-specifically to the blood 
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present in the female’s intestine, thus defaulting the experiment. 24-well culture plates 
were prepared using RPMI–1640 culture medium, 200 mM L-glutamine, 10 mM 
HEPES, 24 mM of NaHCO3, 10,000 UI of Penicillin and 10 mg/mL of Streptomycin, 
from Sigma-Aldrich, pH 7 and supplemented with 15% fetal bovine serum and three 
parasites were added on each well for each studied group. Parasites were incubated 
overnight at 37 °C in a 5% CO2 atmosphere to recover from stress caused by liver 
perfusion. After this period, the worms were washed twice with saline solution to clean 
any traces of culture medium. The worms were then exposed to the inhibitor for 1 h in 
the previous-mentioned concentrations, after which EtBr was added (0.6 μM) and 
parasites were observed under fluorescence microscopy (Zeiss, Axioskop HBO50) for 
a maximum of 35 min and pictures were taken every 2 min. After this period 1 mM of 
CaCl2 was added to reverse the inhibitory effect of Verapamil, pictures were taken 
every two minutes for 35 min, of all worms at the same exact position, magnification 
and fluorescence intensity for overall analysis of the assays. Three control groups were 
used: 1- Without Verapamil, 2 - Without EtBr and 3 - Without both Verapamil and EtBr 
(negative control). Fluorescence was quantified using the ImageJ software and 
compared between different groups. 
3.5. Ex vivo Praziquantel susceptibility assay 
An ex vivo assay was devised to assess the susceptibility of adult worms of S. mansoni 
from both PZQ-susceptible and PZQ-resistant parasite strains, in the presence and 
absence of Verapamil, to ascertain the involvement of Pgp-like EPs in the PZQ 
resistant phenotype. 
Parasites were collected as previously described and separated by sex. 24-well culture 
plates were prepared as described in the previous section and various concentrations 
of PZQ and Verapamil were used in this susceptibility assay (Table II-1). Five worms 
were kept in each well and the same concentration of drug and inhibitor was used in 
two wells of the same plate. The experiment was done in triplicate, with at least 30 
worms used for each concentration of drug and inhibitor. After adding Verapamil and/or 
PZQ, parasites were incubated for another 24 h at 37 °C in a 5% CO2 atmosphere after 
which the medium was switched for a drug free medium and kept for another 48 h. 
Parasites were observed every 12 h and the culture medium was changed after each 
observation. Parasites that did not present any movement after being observed at the 
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microscope for a period of 2 min were considered dead. Lethal doses were calculated 
using the software IBM SPSS Statistics software version 20.0 for Windows using Probit 
regression model with a 95% confidence. The lethal doses obtained were used for 
graphical construction design, using GraphPad Prism software. 
Table II-1. PZQ and Verapamil concentrations used for the ex vivo PZQ susceptibility assay. 
Parasite strains Parasite Sex Verapamil (µM) PZQ (µM) 
Susceptible 
Males 
0.0      0 - 25.6 
0.2      0 - 25.6 
1.1      0 - 25.6 
Females 
0.0         0 - 288.1 
4.4         0 - 288.1 
Resistant 
Males 
0.0         0 - 128.0 
1.1       0 - 64.0 
2.2       0 - 48.0 
4.4       0 - 48.0 
8.8       0 - 32.0 
Females 
0.0 0 - 2880.9 
8.8 0 - 2880.9 
doi:10.1371/journal.pone.0140147.t001 
3.6. RNA extraction and real-time qRT-PCR 
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, California, USA) from 
quick-frozen worms and then treated with DNase from Ambion according to the 
manufacturer’s instructions. Real-time quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) was performed using the PerfectaSYBR Green SuperMix 
for iQ from Quanta Biosciences on an Opticon Real-Time PCR detection system from 
BioRad, according to the manufacturer’s recommendations. Schistosoma mansoni 
18S (Sm18s) ribosomal RNA of each group was used as a reference gene in these 
experiments. Primers used for the amplification of SmMDR2 gene were SmMDR2 F 
(5’-TCTGACAATCGACCTGGTG–3’) and SmMDR2 R (5’-
CCAAGGAAGCAATGACTAAAAC–3’) and for Sm18S gene the primers were Sm18S 
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F (5’-AGGAATTGACGGAAGGGCAC–3’) and Sm18S R 
5’ACCACCCACCGAATCAAGAAAG–3’) [21]. For quantitative measurements, data 
was analyzed using the 2-ΔΔCt method [26] to determine the relative expression ratio 
between target gene (SmMDR2) and reference housekeeping gene (Sm18S), with 
appropriate calibrators and corrections for amplification efficiency. Three biological and 
technical replicates were used for the qRT-PCR experiments. 
3.7. Statistical analysis 
Data were expressed as mean ± standard deviation (SD), and tested for statistical 
significance using either ANOVA or unpaired t-tests. Probit regression model with a 
95% confidence was used to calculate the lethal doses, and the graphic construction 
was performed using GraphPad Prism 5.0 software. 
3.8. Ethics statement 
This research project was reviewed and approved by the Ethics Committee and Animal 
Welfare, Faculty of Veterinary Medicine, UL (Ref. 0421/2013). Animals were 
maintained and handled in accordance with National and European legislation (DL 
276/2001 and DL 314/2003; 2010/63/EU adopted on 22nd September 2010), with 
regard to the protection and animal welfare, and all procedures were performed 
according to National and European legislation. The anesthetics and other techniques 
were used to reduce the pain and adverse effect of animal.  
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4.  Results 
4.1. Ethidium Bromide efflux assay 
Efflux pump activity was compared between PZQ-resistant and PZQ-susceptible adult 
males through fluorescence microscopy observation. EtBr is a common substrate to 
all EPs, when outside the cells the signal is low, but when inside, the signal is amplified, 
and can be detected and quantified by time-course fluorescence spectroscopy [27]. 
Intracellular accumulation of EtBr after efflux inhibition by Verapamil was assessed by 
the increases in fluorescence intensity, using ImageJ software. As shown in Figure II-4 
in the susceptible variant strain after exposure to 2.2 μM of Verapamil, the efflux of 
EtBr was inhibited resulting in a clear increase of fluorescence, which decreased after 
the addition of CaCl2. Verapamil is known to block the flow of Calcium ions by binding 
to putative Ca2+ binding site [28–31], the addition of Calcium revealed a reversing effect 
on the Verapamil inhibitory action on the efflux of EtBr, apparently restoring the function 
of the adult worms EPs, thus reinforcing the hypothesis raised that the observed 
accumulation of EtBr in the adult males was due to the effect of this inhibitor on 
Calcium-dependent transporters, possibly by indirectly interfering with Calcium-
dependent Pgp ATPases [28–31]. The control groups without EtBr showed viability 
and no intrinsic fluorescence was observed thus it is not represented. These findings 
are of importance considering that Pgp and MRPs are members of the “traffic ATPase” 
superfamily, which use the energy of ATP hydrolysis for maintaining their membrane 
transport function. 
In the PZQ-resistant parasite strain, after exposure to 2.2 μM of Verapamil, there was 
an initial increase in fluorescence that later stabilized, showing EtBr accumulation 
levels lower than the PZQ-susceptible strain. A decrease in fluorescence was noticed 
after exposure to CaCl2. Only by exposing the PZQ-resistant strain to 4.4 μM of 
Verapamil, fluorescence levels reached levels similar to the susceptible parasites 
(Figure II-5). 
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Figure II-4. EtBr efflux assay in adult males of S. mansoni PZQ-susceptible strain. A) Control group 
- worms exposed to 0.6 μM of EtBr (20 min); B) Worms exposed to 2.2 μM of Verapamil and 0.6 μM of 
EtBr (20 min); C) Worms exposed to 2.2 μM of Verapamil, 0.6 μM of EtBr, and 1 mM de CaCl2 (35min). 
doi:10.1371/journal.pone.0140147.g004. 
 
 
Figure II-5. EtBr efflux assay in adult males of S. mansoni PZQ-resistant strain. A) Control group 
- worms exposed to 0.6 μM of EtBr (20 min); B) Worms exposed to 2.2 μM of Verapamil and 0.6 μM of 
EtBr (20 min); C) Worms exposed to 4.4 μM of Verapamil and 0.6 μM of EtBr (20 min); D) Worms 
exposed to 4.4 μM of Verapamil, 0.6 μM of EtBr, and 1 mM de CaCl2 (35 min). 
doi:10.1371/journal.pone.0140147.g005. 
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As described in the Material and Methods section of this Chapter, throughout the efflux 
assays, fluorescence microscopy images were taken every 2 min for 35 min. 
Fluorescence was quantified in each picture in three areas of the worm central section 
(below the cecum ramification), as shown in Figure II-3, and background fluorescence 
was subtracted for each parasite (n = 9) at each time-points. The average was 
calculated and real-time efflux graphics were created to obtain an EtBr accumulation 
time course in presence and absence of Verapamil in both variant strains (Figure II-6, 
Figure II-7 and Figure II-8). In the PZQ-susceptible parasite strain exposure of the 
worms to 2.2 μM of Verapamil allowed us to observe a steady increase in the 
fluorescence over time, reaching approximately twice the mean relative fluorescence 
levels after 20 min, once compared to parasites not exposed to Verapamil. After the 
addition of 1 mM CaCl2 a sharp decrease in the fluorescence levels, reaching the same 
levels of those parasites not exposed to Verapamil (Figure II-6). 
 
Figure II-6. Variation in EtBr accumulation (Mean relative fluorescence) in the presence and 
absence of Verapamil and after the addition of CaCl2 in S. mansoni PZQ-susceptible adult males. 
Three worms were used for each group and the experiment was performed three times. Quantification 
measurements were made in three areas of the worm central section (below the cecum ramification) 
and background fluorescence was subtracted for each parasite at each time-point. The average 
measurement was calculated for each time-point. Data are expressed as mean fluorescence of the EtBr 
accumulated intracellularly over time. 
doi:10.1371/journal.pone.0140147.g006 
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In the PZQ-resistant strain, for the parasites exposed to 2.2 μM of Verapamil, there 
was an increase in fluorescence in the first 16 min, then maintaining a constant 
fluorescence over time at lower levels than the susceptible strain. No decrease in 
fluorescence was observed upon addition of 1 mM CaCl2 (Figure II-7). Once exposed 
to 4.4 μM of Verapamil, the parasites showed a steady increase in the mean 
fluorescence over time (Figure II-8). The PZQ-resistant parasite strain only showed 
fluorescence accumulation levels similar to the PZQ-susceptible strain when exposed 
to twice the concentration of Verapamil. 
 
Figure II-7. Variation in EtBr accumulation (Mean relative fluorescence) in the presence and 
absence of Verapamil and after CaCl2 addition in S. mansoni PZQ-resistant adult males. Three 
worms were used for each group and the experiment was performed three times. Quantification 
measurements were made in three areas of the worm central section (below the cecum ramification) 
and background fluorescence was subtracted for each parasite at each time-point. The average 
measurement was calculated for each time-point. Data are expressed as mean fluorescence of the EtBr 
accumulated intracellularly over time. 
doi:10.1371/journal.pone.0140147.g007 
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Figure II-8. Variation in EtBr accumulation (Mean relative fluorescence) in the absence and 
presence of 2.2 μM and 4.4 μM of Verapamil in S. mansoni PZQ-resistant adult males. Three 
worms were used for each group and the experiment was performed three times. Quantification 
measurements were made in three areas of the worm central section (below the cecum ramification) 
and background fluorescence was subtracted for each parasite at each time-point. The average 
measurement was calculated for each time-point. Data are expressed as mean fluorescence of EtBr 
accumulated intracellularly over time. 
doi:10.1371/journal.pone.0140147.g008 
 
4.2. Ex vivo Praziquantel susceptibility assay 
PZQ-susceptible male worms. In the absence of Verapamil, adult males of the PZQ-
susceptible strain achieved a 50% lethal dose (LD50) when exposed to 17.8 μM of 
PZQ; a lethal dose of 90% (LD90) when exposed to 24.2 μM of PZQ and a lethal dose 
of 99% (LD99) when exposed to 31.0 μM of PZQ. In the presence of Verapamil, it was 
possible to observe a reduction in the amount of PZQ required to achieve the lethal 
doses mentioned above. In the presence of 0.2 μM and 1.1 μM of Verapamil the LD50 
was 15.1 μM and 12.5 μM of PZQ, respectively. LD90 was 20.6 μM and 16.9 μM of 
PZQ, and LD99 was 26.4 μM and 21.7 μM of PZQ, respectively (Table II-2). 
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Table II-2. Lethal doses of PZQ (LB - Lower bound; UB - Upper bound) calculated using Probit 
regression model with a 95% confidence, for S. mansoni PZQ-susceptible males in the presence 
of different concentrations of Verapamil. 
Verapamil 
Concentration 
(µM) 
Mortality (%) 
1 10 30 50 70 90 99 
PZQ Concentration (µM) 
0 10.2 
(LB – 
8.37; UB 
– 11.21) 
13.1 
(LB – 
10.53; 
UB – 
15.00) 
15.7 
(LB – 
13.41; 
UB – 
17.70) 
17.8 
(LB – 
15.62; 
UB – 
20.15) 
20.2 
(LB – 
17.89; 
UB – 
23.34) 
24.2 
(LB – 
21.21; 
UB – 
29.58) 
31.0 
(LB – 
26.14; UB 
– 40.11) 
0.2 8.7 
(LB – 
6.11; UB 
– 10.53) 
11.1 
(LB – 
8.73; 
UB – 
12.94) 
13.4 
(LB – 
11.16; 
UB – 
15.21) 
15.1 
(LB – 
13.06; 
UB – 
17.24) 
17.2 
(LB – 
15.05; 
UB – 
19.83) 
20.6 
(LB – 
17.99; 
UB – 
24.83) 
26.4 
(LB – 
22.32; UB 
– 35.26) 
1.1 7.2 
(LB – 
5.06; UB 
– 8.66) 
9.2 
(LB – 
7.22; 
UB – 
10.64) 
11.0 
(LB – 
9.52; 
UB – 
12.52) 
12.5 
(LB – 
10.78; 
UB – 
14.21) 
14.1 
(LB – 
12.41; 
UB – 
16.37) 
16.9 
(LB – 
14.82; 
UB – 
20.60) 
21.7 
(LB – 
18.26; UB 
– 29.37) 
doi:10.1371/journal.pone.0140147.t002 
The lethal dose (LD) values calculated using PZQ-susceptible parasite strain adult 
males were applied for the construction of mortality trend curves to get a better view 
of Verapamil effect on their susceptibility to PZQ (Figure II-9). A decrease in the PZQ 
concentration required to achieve the same level of mortality was evident once 
compared to parasites not exposed to the inhibitor. 
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Figure II-9. Mortality trends of S. mansoni adult males PZQ-susceptible exposed to PZQ in the 
presence of Verapamil. The mortality levels to increase concentrations of Verapamil (0.2 and 1.1 μM) 
are represented by survival curves. Additionally, the survival curve of parasites unexposed to Verapamil 
is also represented. The Probit regression model was used with a 95% of confidence. 
doi:10.1371/journal.pone.0140147.g009 
PZQ-resistant male worms. In the absence of Verapamil, male worms of the PZQ-
resistant strain achieved the LD50 when exposed to 65.2 μM of PZQ, LD90 when 
exposed to 98.1 μM and the LD99 when exposed to 137.0 μM of PZQ. 
When exposed to a non-toxic concentration of Verapamil, it was possible to observe a 
reduction in the amount of PZQ required to achieve the lethal doses mentioned above. 
In the presence of four different concentrations of Verapamil (1.1 μM, 2.2 μM, 4.4 μM, 
and 8.8 μM), the PZQ lethal dose decreased significantly: LD50 concentrations of PZQ 
was 33.9 μM, 19.7 μM, 5.1 μM and 3.6 μM, LD90 was 52.4 μM, 37.5 μM, 19.8 μM and 
12.8 μM and the LD99 was 74.7 μM, 63.2 μM, 59.8 μM and 35.9 μM, for each of the 
four concentrations of inhibitor used (Table II-3). 
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Table II-3. Lethal doses of PZQ (LB-Lower bound; UB-Upper bound) calculated using Probit 
regression model with a 95% confidence, for S. mansoni PZQ-resistant parasite strain males in 
the presence of various concentrations of Verapamil. 
Verapamil 
Concentration 
(µM) 
Mortality (%) 
1 10 30 50 70 90 99 
PZQ Concentration (µM) 
0 30.98 
(LB – 
22.30; 
UB – 
37.51) 
43.27 
(LB – 
35.15; 
UB – 
49.15) 
55.11 
(LB – 
48.34; 
UB – 
60.44) 
65.16 
(LB – 
59.27; 
UB – 
70.95) 
77.05 
(LB – 
70.76; 
UB – 
85.51) 
98.14 
(LB – 
87.99; 
UB – 
116.32) 
137.03 
(LB – 
115.75; 
UB – 
182.62) 
1.1 15.39 
(LB – 
9.91; 
UB – 
19.23) 
21.95 
(LB – 
15.62; 
UB – 
28.42) 
28.38 
(LB – 
25.42; 
UB – 
31.37) 
33.92 
(LB – 
27.81; 
UB – 
37.76) 
40.53 
(LB – 
38.20; 
UB – 
52.21) 
52.41 
(LB – 
45.26; 
UB – 
58.07) 
74.74 
(LB – 
64.41; 
UB – 
84.63) 
2.2 6.16 
(LB –
1.46; 
UB – 
9.83) 
10.38 
(LB – 
4.34; 
UB – 
14.20) 
15.17 
(LB – 
9.21; 
UB – 
19.18) 
19.72 
(LB – 
14.55; 
UB – 
25.21) 
25.64 
(LB – 
20.38; 
UB – 
37.35) 
37.46 
(LB – 
28.43; 
UB – 
76.87) 
63.20 
(LB – 
41.46; 
UB – 
88.66) 
4.4 0.44 
(LB – 
0.08; 
UB – 
1.02) 
1.33 
(LB – 
0.42; 
UB – 
2.35) 
2.95 
(LB – 
1.42; 
UB – 
4.37) 
5.13 
(LB – 
3.18; 
UB – 
6.93) 
8.92 
(LB – 
6.56; 
UB – 
11.95) 
19.85 
(LB – 
14.44; 
UB – 
34.00) 
59.81 
(LB – 
34.70; 
UB – 
67.70) 
8.8 0.36 
(LB – 
0.02; 
UB – 
0.94) 
1.01 
(LB – 
0.38; 
UB – 
1.86) 
2.15 
(LB – 
1.25; 
UB – 
3.00) 
3.60 
(LB – 
2.98; 
UB – 
4.98) 
6.05 
(LB – 
5.35; 
UB – 
9.02) 
12.79 
(LB – 
10.18; 
UB – 
17.60) 
35.94 
(LB – 
22.72; 
UB – 
40.65) 
doi:10.1371/journal.pone.0140147.t003 
The lethal PZQ dose values for PZQ-resistant males when exposed to different 
concentrations of Verapamil were plotted in a mortality dose dependent curve (Figure 
II-10), showing the effect of Verapamil on the susceptibility to PZQ in this variant strain. 
Once again, in the presence of the efflux inhibitor (Verapamil), a decrease in the PZQ 
concentration required to achieve the same level of mortality was observed, compared 
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to parasites not exposed to this inhibitor. In the presence of 1.1 μM of Verapamil, the 
lowest concentration tested in this strain, the PZQ lethal concentrations were twice as 
low compared to the ones obtained for the group not exposed to the inhibitor. Overall, 
it was demonstrated that the drug-resistant strain reduces or reverts its resistance to 
PZQ in the presence of Verapamil obtaining LD values close to or even lower than 
those obtained for the susceptible variant strain. 
 
Figure II-10. Mortality trends of S. mansoni adult males PZQ-resistant exposed to PZQ in the 
presence of Verapamil. The mortality levels to increase concentrations of Verapamil (1.1–8.8 μM) are 
represented by survival curves. Additionally, the survival curve of parasites unexposed to Verapamil is 
also represented. The Probit regression model was used with a 95% of confidence. 
doi:10.1371/journal.pone.0140147.g010 
PZQ-susceptible female worms. In the absence of Verapamil, susceptible strain 
females presented a LD50 of 205.02 μM, a LD90 of 230.84 μM, and a LD99 of 254.29 
μM of PZQ (Table II-4). When exposed to the highest concentration of Verapamil used 
in this study (4.4 μM), no differences in PZQ susceptibility were noticed (Figure II-11). 
Our results put in evidence that PZQ-susceptible female worms are more resistant to 
PZQ than males from the resistant strain. 
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Table II-4. Lethal doses of PZQ (LB—Lower bound; UB—Upper bound) calculated using Probit 
regression model with a 95% confidence, for S. mansoni PZQ-susceptible parasite strain females 
in the presence of different concentrations of Verapamil. 
Verapamil 
Concentration 
(µM) 
Mortality (%) 
1 10 30 50 70 90 99 
PZQ Concentration (µM) 
0 165.29 
(LB – 
156.91; 
UB – 
171.61) 
182.08 
(LB – 
176.07; 
UB – 
186.74) 
195.30 
(LB – 
190.94; 
UB – 
199.00) 
205.02 
(LB – 
201.34; 
UB – 
208.62) 
215.21 
(LB – 
211.43; 
UB – 
219.61) 
230.84 
(LB – 
225.60; 
UB – 
237.86) 
254.29 
(LB – 
245.62; 
UB – 
266.75) 
4.4 159.22 
(LB – 
150.43; 
UB – 
168.33) 
178.33 
(LB – 
166.08; 
UB – 
181.26) 
193.52 
(LB – 
189.62; 
UB – 
195.99) 
204.76 
(LB – 
200.25; 
UB – 
208.55) 
216.62 
(LB – 
209.86; 
UB – 
219.01) 
234.90 
(LB – 
230.22; 
UB – 
238.73) 
252.98 
(LB – 
244.44; 
UB – 
263.93) 
doi:10.1371/journal.pone.0140147.t004 
Although the concentration of PZQ associated with female worm data seems high, 
PZQ used ex vivo is not metabolized, and PZQ metabolites have shown a higher anti-
schistosomal activity than pure unmetabolized PZQ (used in vitro) [32]. 
It should also be noticed that Schistosoma females have a much higher tolerance to 
PZQ than males as shown by Pica-Mattoccia and Cioli [33] and by Liang and 
colleagues [34]. The results we obtained for LD50 in females stays somewhere in 
between the ones obtained by these authors. 
PZQ-resistant female worms. PZQ-resistant female worms were exposed to PZQ 
concentrations up to 2880.92 μM, in the presence and absence of Verapamil, and it 
was not possible to determine any lethal doses. However, long-term effects of PZQ 
and the effects of the host immune system were not taken into account. 
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Figure II-11. Mortality trends S. mansoni adult females PZQ-susceptible exposed to PZQ in the 
presence of Verapamil. The mortality levels to 4.4 μM Verapamil is represented by a survival curve. 
Additionally, the survival curve of parasites unexposed to Verapamil is also represented. The Probit 
regression model was used with a 95% of confidence. 
doi:10.1371/journal.pone.0140147.g011 
 
4.3. Real-time qRT-PCR 
The relative expression levels of SmMDR2 gene were assessed using a qRT-PCR 
method. Adult worms of each PZQ-strain were separated by sex and compared. 
Parasites were also compared in the presence and absence of 0.3 μM of PZQ for 3 h. 
As shown in Figure II-12, when comparing PZQ-susceptible males and females, before 
exposure to PZQ, females showed a relative increase in the expression level of 
SmMDR2 of approximately 4 times, when compared to males (p < 0.05). When 
exposed to PZQ the expression level of SmMDR2 in susceptible males increased 17 
times when compared to the expression level of the same gene in the absence of PZQ 
in females (p < 0.05). As expected, PZQ-resistant males showed, in the absence of 
PZQ, an increase in the expression level of SmMDR2 of approximately 32 times when 
compared to PZQ-susceptible males (p < 0.05). Furthermore, after exposure to PZQ, 
SmMDR2 expression level of PZQ-resistant males was approximately 6 times higher 
than in the absence of PZQ (p < 0.05). Finally, PZQ-resistant females showed no 
significant change in SmMDR2 expression after exposure to PZQ (p > 0.05), and the 
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expression was approximately 10 times lower than the PZQ-susceptible females (p < 
0.05). 
In the EtBr efflux assay, when observing both PZQ-susceptible and PZQ-resistant 
adult males, fluorescence levels in the absence of Verapamil, did not vary significantly, 
however when observing the expression of SmMDR2 through qRT-PCR, there was a 
significant difference in SmMDR2 expression. However we believe this could be 
explained by a higher sensitivity of qRT-PCR. 
 
Figure II-12. Relative expression level of SmMDR2 in males and females of PZQ-susceptible and 
PZQ-resistant parasite strains in the presence and absence of PZQ. White bars - level expression 
of SmMDR2 in adult worms without exposure to PZQ, and black bars - level expression of SmMDR2 in 
adult worms after exposure to PZQ. The n-fold changes were determined by qRT-PCR using S. mansoni 
18S (Sm18s) of each group as a reference gene. Differences of the relative level of SmMDR2 between 
the groups was done using ANOVA and unpaired t-test, p < 0.05. 
doi:10.1371/journal.pone.0140147.g012  
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5. Discussion 
We have selected, for the first time, to our knowledge, a stable PZQ-resistant parasite 
strain that resists to 1,200 mg/kg of PZQ. This strain was obtained by PZQ continuous 
drug pressure, and this PZQ-resistant parasite strain was used to analyze the 
involvement of EPs in the observed induced PZQ-drug resistance phenotype. EPs 
activity of S. mansoni adult male worms, was observed and monitored by fluorescence 
microscopy using for the first time an adaptation of the semi-automated fluorometric 
methodology described by Viveiros and colleagues [25]. EtBr was used as a universal 
fluorescent substrate in the presence and absence of an efflux inhibitor – Verapamil, 
thus the emission of the accumulated fluorescence was monitored throughout 
sequential photographs, taken every 2 min, during a maximum period of 35 min. This 
assay was only possible to perform with adult males, because EtBr binds non-
specifically to the blood present in the female’s intestine, turning impossible to 
distinguish differences of EPs activity in the female worms [35]. 
In PZQ-susceptible adult males, the exposure to 2.2 μM of Verapamil led to a 
substantial increase in accumulated fluorescence suggesting that Verapamil is able to 
inhibit EtBr efflux in S. mansoni males of the susceptible strain. Reversal of this effect 
was possible after the addition of a non-toxic concentration of CaCl2, suggesting that 
CaCl2 has an important role in the mechanism responsible for reversing the efflux 
inhibitory effect of Verapamil in Schistosoma spp. This involvement of Calcium ions 
has been previously described in the literature [28–31] with a possible relation between 
Calcium homeostasis and Pgp mediated MDR reported by Sulová and colleagues [30]. 
At present, there is no scientifically accepted mechanism by which Calcium reverses 
the effects of Verapamil on Pgp activity, but our novel observation raises questions 
that will be explored in future works, namely the connection between Calcium 
homeostasis, Pgp activity and energy/ATP synthesis used for active transport of 
substrates [29, 30]. In PZQ-resistant adult males EtBr accumulation was up to 2 times 
lower than the PZQ-susceptible males, when exposed to 2.2 μM of Verapamil. Only 
when PZQ-resistant adult males were exposed to 4.4 μM of Verapamil the intracellular 
accumulation of EtBr was similar to the susceptible variant strain. This suggests that 
males of the resistant strain have a higher number of transporters responsible for the 
EtBr efflux, which was further demonstrated by the qRT-PCR results on the SmMDR2 
expression level. Other authors have also shown an increased expression level of the 
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SmMDR in PZQ-resistant clinical isolates of S. mansoni [19, 21, 22, 36, 37]. Here in 
this work, we were able to demonstrate that there is an increase of Pgp-like EPs activity 
in male worms from resistant strain which is in agreement with our results obtained by 
qRT-PCR for parasites exposed for 3 h with sub lethal concentrations of PZQ and 
correlation to its reduced susceptibility to PZQ. Messerli and colleagues [22] observed 
an increase of SmMDR2 mRNA in females after being exposed to PZQ for 24–48 h, 
which were not coincident with expression of SmMDR2 protein. Despite the absence 
of the assay of SmMDR2 expression at protein level our ex vivo PZQ susceptibility 
assay suggests that Pgp-like proteins do not play a relevant role on PZQ-susceptibility 
in female worms. 
The greatest advantage of our experimental model over other PZQ-resistant parasites 
described in the literature is the fact that they are isogenic allowing comparing the 
influence of EPs in PZQ resistant phenotype within the same genetic background. 
Therefore, it was possible to observe that the S. mansoni adult males variant resistant 
to PZQ presented an increased efflux pump activity suggesting that Pgp-like EPs play 
an important role in PZQ-drug resistance in S. mansoni. In the EtBr efflux assay, when 
observing both PZQ-susceptible and PZQ-resistant adult males, fluorescence levels in 
the absence of Verapamil, resistant strain males showed lower levels of fluorescence. 
This could be explained by a higher number of EtBr EPs in the resistant strain, which, 
is further reinforced when observing the expression of SmMDR2, through qRT-PCR, 
where a significant difference in SmMDR2 expression can be observed. To further put 
in evidence that over-expression of EPs is involved in PZQ acquired drug-resistance, 
an ex vivo assay, using both S. mansoni strains, was performed to assess the degree 
of susceptibility of the adult parasites to PZQ, in the presence and absence of 
Verapamil. When adult males of susceptible strain were exposed to Verapamil the PZQ 
concentration required to reach lethal doses was lower than those observed in the 
absence of the inhibitor. Other authors have already reported that blocking the activity 
of the Pgp and MRPs transporters by Verapamil increases the pharmacological 
susceptibility of helminths such as Caenorhabditis elegans, Haemonchus contortus, 
and Cooperia oncophora to various anthelminthic drugs [38, 39]. For male worms of 
PZQ-resistant strain, in the presence of this efflux inhibitor, a lower PZQ concentration 
was required to achieve the same level of mortality compared to the same parasites 
not exposed to the inhibitor. In the presence of the lowest concentration of Verapamil 
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tested in the resistant strain, PZQ lethal concentrations were twice as low as the ones 
obtained for the group not exposed to the inhibitor. 
Overall, it was possible to observe that PZQ susceptibility of the PZQ-resistant strain, 
in the presence of Verapamil, has LD values close to or even lower than those obtained 
for the PZQ-susceptible strain. Ardelli and Prichard also showed that a C. elegans 
Ivermectin-resistant strain in the presence of Verapamil, presented an increased 
susceptibility to Ivermectin, suggesting an involvement of Pgp-like EPs on this 
Ivermectin drug resistant phenotype [38]. Our results also suggest that, just as in the 
resistant strain of C. elegans, the adult males of our resistant strain have Pgp pumps 
involved in the drug resistance phenotype as demonstrated by the SmMDR2 
expression level analysis. 
It is reported in literature collateral sensitivity of drug-resistant cancer cells to 
Verapamil [40–42], a phenomenon that might have happened in our ex vivo PZQ 
susceptibility assay in PZQ-resistant worms by a mechanism possibly linked to the 
expression of SmMDR2. This weakness observed by PZQ LD50 obtained from 
resistant worms in the presence of increasing concentrations of Verapamil, can 
circumvent potential problems that might be associated with adjuvant therapy using 
EPs inhibitors during standard therapy with PZQ, where the main objective is to treat 
patients by killing all the worms (susceptible and resistant worms) without causing side 
effects. Also, collateral sensitivity opens a new approach for the identification of new 
re-sensitizing compounds in the management of PZQ-resistance and to elucidate the 
mechanisms involved. 
In contrast, female adult worms did not present any difference in the observed lethal 
doses of PZQ, in the presence or in absence of Verapamil, which gives an indication 
that the activity of Pgp-like EPs is not involved in PZQ susceptibility of adult female 
worms. Furthermore, the values obtained for lethal dose suggests a higher tolerance 
of female worms to PZQ. This higher tolerance has already been described in other 
reports [21, 33, 36] in which adult female worms tolerate considerably higher 
concentrations of PZQ than adult males both ex vivo and in vivo [9, 11, 12, 43, 44, 45]. 
Previous studies regarding drug resistance, have already presented evidence of an 
increased tolerance to PZQ in male worms [19, 21, 22, 36, 37, 46]. It should be noted 
that when using in vitro and ex vivo assays the interaction between the effects caused 
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by the drug and those caused by the host immune system on the parasite are not taken 
in consideration [33, 47, 48]. In conclusion, our work describes for the first time, the 
application of a successful methodology previously applied in bacteria and cancer 
cells, using the universal efflux pump substrate EtBr, for the evaluation of drug 
transporter systems on S. mansoni adult worms as a multicellular cell model using an 
ex vivo assay. The methodology used have demonstrated the involvement of adult 
male schistosomes Pgp-like transporters SmMDR2 in PZQ drug resistance phenotype, 
evidenced by the fact that lower doses of Verapamil successfully reverted PZQ drug 
resistance when using sub lethal concentrations of PZQ. World Health Organization 
warns about the possible emergence of Schistosoma spp. populations that are 
resistant to PZQ, thus recommending continued vigilance [49]. Therefore, studies on 
genetic resistance mechanisms against PZQ are of extreme importance to understand 
the potential mechanism(s) of resistance/increased tolerance to PZQ, contributing to 
the development of new drugs and the delineation of new strategies for 
schistosomiasis control.  
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1. Abstract 
Schistosomiasis is one of the most common human parasitic diseases whose 
socioeconomic impact is only surpassed by malaria. PZQ is the only drug commercially 
available for the treatment of all schistosome species causing disease in humans. 
However, there are strong evidences of PZQ-resistance on S. mansoni and thus it is 
very important to study the phenotypic characteristics associated with it. The aim of 
this study was to evaluate morphological alterations in S. mansoni PZQ-resistant adult 
worms and eggs, by comparing a PZQ-resistant strain obtained under PZQ drug 
pressure with a PZQ-susceptible strain. For this, SEM was used to assess tegumental 
responsiveness of both strains under PZQ exposure, and optical microscopy allowed 
the monitoring of worms and eggs in the presence of the drug. Those assays showed 
that PZQ-susceptible worms exposed to the drug had more severe tegumental 
damages than the resistant one, which had only minor alterations. Moreover, contrary 
to what occurred in the susceptible strain, resistant worms were viable after PZQ 
exposure and gradually regaining full motility after removal of the drug. Eggs from 
resistant strain parasites are considerably smaller than those from susceptible strain. 
Our results suggest that there might be a difference in the tegument composition of the 
resistant strain and that those worms are less responsive to PZQ. Changes observed 
in egg morphology might imply alterations in the biology of schistosomes associated 
to PZQ-resistance, which could have impact on transmission and pathology of the 
disease. Moreover, we propose a hypothetical scenario where there is a different egg 
tropism of the S. mansoni resistant strain. This study is the first comparing the 
morphology of two strains that only differ in their resistance characteristics, which 
makes it a relevant step in the search for resistance determinants.  
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2. Introduction 
Schistosomiasis is considered one of the most common human parasitic diseases, 
registering high rates of morbidity in about 20 million people, and about 280 000 deaths 
annually, especially in tropical and subtropical countries, namely African countries, 
countries of the Middle East, Caribbean, Brazil, Venezuela, Suriname, and other 
countries such as China, Indonesia and the Philippines [1-4]. The disease transmission 
invariably occurs when people suffering from schistosomiasis contaminate freshwater 
with their excreta containing parasite eggs, which hatch in water. People become 
infected when larval forms of the parasite (cercariae) penetrate the skin during contact 
with freshwater, usually by swimming or washing [5]. 
Schistosome infections can cause severe damage to various organs, mostly intestine, 
bladder, liver, brain and spinal cord, and cause significant morbidity, impair childhood 
development and adult productivity, potentially increase susceptibility to other 
infections such as HIV, and, in some cases, lead to death [1, 6-10]. Infrastructural and 
educational awareness can be highly effective to control schistosomiasis, however 
they are expensive and require levels of organization that are difficult in most 
developing countries [11]. The use of molluscicides to eliminate intermediate host 
snails is another important control method, but it is also costly and often produces 
limited and short-term effectiveness [12], as well as may have some negative 
environmental impacts. Therefore, because there is no available vaccine or 
prophylaxis, current control of schistosomiasis is based only on chemotherapy using 
PZQ [13]. 
PZQ is the only antischistosomal drug commercially available for the treatment of all 
human schistosome species [11, 14-16] and it presents important advantages such as 
mild side effects and relatively low cost [9]. PZQ has been available for several 
decades and large-scale PZQ treatment programs have produced significant 
reductions in both disease prevalence and intensity [17-19]. However, dependence on 
a single drug, which would be inadvisable for any infectious condition, is in the case of 
a disease with such high prevalence as schistosomiasis [20] a major concern, because 
it might induce the appearance of drug-resistant/tolerant parasites [21-25]. 
So far, the mechanism involved in the phenomenon of resistance to PZQ is not yet 
fully understood, there is only descriptions and evidences of this phenomenon in in 
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vivo and ex vivo studies. For instance, Fallon and Doenhoff [26], produced a S. 
mansoni PZQ-resistant strain in only two generations after repeated exposure to sub-
lethal doses of the drug through in vivo artificial selection in mice. Furthermore, low 
cure rates in response to PZQ emerged 10-15 years ago after mass scale use in 
countries like Egypt and Senegal [27, 28] and worms from non-cured patients were 
repeatedly less susceptible to PZQ when tested in mice [29]. 
De Oliveira and colleagues [30], evaluated the effect of PZQ on the morphology of 
adult S. mansoni susceptible to PZQ and observed that parasites exposed to the drug 
showed tegumental changes apparent in all male and female worms. They observed 
destruction of tubercles with loss of thorns and formation of vesicles around the 
tubercles. Since the tegument of adult Schistosoma is a protective sheath that plays a 
role in defense, as well as in the uptake of nutrients, osmoregulation and excretion, 
damages in this structure may have major consequences to parasite viability. Thus, 
morphological studies are important to clarify aspects of drug-induced damages [31]. 
We have obtained in our laboratory by stepwise drug pressure a PZQ-resistant 
parasite strain (IHMT/UNL) from the fully PZQ-susceptible parasite BH strain. This S. 
mansoni variant strain is more resistant to PZQ than the original susceptible one and 
this resistant phenotype is stable in the absence of the drug pressure. This resistant 
parasite variant strain, obtained from infected mice, tolerates up to 1,200 mg PZQ/kg 
of mouse body weight and is isogenic to its fully susceptible parental counterpart, 
except for the genetic determinants accounting for the PZQ-resistance phenotype [32]. 
Besides that, data resulting from earlier study [32] suggested that the S. mansoni PZQ-
resistant strain has different ex vivo susceptibility to PZQ and that this difference varied 
greatly between male and female worms. In this context, the objective of this study 
was to evaluate morphological alterations in the S. mansoni PZQ-resistance 
phenotype by comparing the PZQ-resistant strain obtained under PZQ drug pressure 
with the PZQ-susceptible strain.  
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3. Material and Methods 
3.1. Praziquantel 
PZQ was purchased from Merck & Co. (Kenilworth, NJ, USA) and dissolved in 1% 
DMSO from Sigma-Aldrich according to [33], used for stock solution, which was 
subsequently diluted to appropriate concentrations in culture media. 
3.2.  Parasite isolation and animal model  
In this study we used two parasite strains, the S. mansoni BH strain, susceptible to 
PZQ, and a stable PZQ-resistant strain (IHMT/UNL) obtained from the BH strain as 
described in the Chapter II [32]. Briefly, our stable PZQ-resistant parasite strain was 
obtained from the BH line submitted to various steps of PZQ continuous drug pressure, 
starting with a sub therapeutic dose and finishing with 1,200 mg/kg of PZQ. Infected 
CD1 mice were checked approximately 60 days post parasite infection by Kato-Katz 
procedure. If eggs were found in feces, mice were then treated orally with PZQ solution 
at appropriate dose. If, on day 15, post PZQ treatment, viable eggs (verified by live 
miracidium inside the eggs and Kato-Katz procedure) continued to be eliminated, mice 
were euthanized and eggs present in the liver were used to obtain miracidium to 
subsequently infect B. glabrata snails. Once B. glabrata snails start eliminating S. 
mansoni cercariae (30 to 60 days after snail infection), new CD1 mice were re-infected 
and the previous procedure was repeated, continuing the PZQ-resistant strain 
selection in vivo. PZQ dose was increased every two passages. These two parasite 
strains are routinely kept in their intermediate host B. glabrata snails at our laboratory 
at IHMT/UNL. 
Mus musculus CD1 line male mice are considered the choice animal model for S. 
mansoni infection, because it is highly susceptible to this parasite as it closely 
resembles the S. mansoni human infection [34]. The infection occurred by 
percutaneous exposure of mice tails to about 100 cercariae of S. mansoni each, 
through natural transdermal penetration of the cercariae [35]. 
Adult worms (8-10 weeks post-infection) were collected through hepatic portal system 
and mesenteric veins perfusion, according to [35], washed in saline solution and then 
maintained in a RPMI medium (Sigma-Aldrich). The Figure III-1 explains in more detail 
the experimental design performed in this chapter. 
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Figure III-1. Schematic cartoon of the experimental design. (1) B. glabrata snails (intermediate hosts 
of S. mansoni) release the infective form of the parasite (cercariae) for human or other mammalian 
definitive hosts; (2) About 100 cercariae were used to infect the definitive host; (3) CD1 Mice were used 
as definitive host in our experiment, and after 8-10 weeks post-infection they were sacrificed to collect 
adult worms of the parasite; (4) Adult worms were obtained by mice liver perfusion; (5) Male and female 
worms were treated in 24-well culture plate with a dose of PZQ (0.3 μM) with impact in the parasite but 
with the guarantee of not killing them. These worms were prepared for PZQ-induced tegumental 
alterations study using SEM; (6) Couple worms were treated in 24-well culture plate with a lethal dose 
of PZQ (32 μM). These worms were analyzed and monitored under an inverted optical microscope. The 
B. glabrata, cercariae and adult worms’ photos were offered by Dr. Pedro Ferreira (IHMT/UNL). 
3.3.  Ex vivo treatment with Praziquantel  
After collection, adult worm parasites were transferred to 24-well culture plates 
containing RPMI-1640 culture medium, 200 mM L-glutamine, 10 mM HEPES, 24 mM 
of NaHCO3, 10,000 UI of Penicillin and 10 mg/mL of Streptomycin, from Sigma-Aldrich, 
pH 7, and supplemented with 15% fetal bovine serum. About five parasites, individually 
or as a couple, were added to each well and the same concentration of drug was used 
in two wells. All experiments were carried out in tree biological replicates, ten on each 
replicate (n = 30) for each studied group: 1) PZQ-susceptible male worms, 2) PZQ-
susceptible female worms, 3) PZQ-resistant male worms, 4) PZQ-resistant female 
worms, 5) PZQ-susceptible couple worms, and 6) PZQ-resistant couple worms. 
Parasites were incubated overnight at 37 ºC in a 5% CO2 atmosphere to recover from 
stress caused by perfusion. After this period, male and female worms were treated in 
culture with a dose of PZQ (0.3 μM, for 3 h) with impact in the parasite, but with the 
guarantee of not killing them, then washed twice with saline solution to clean any traces 
of culture medium and prepared for SEM. Couple worms of both strains were treated 
ex vivo with a lethal dose of PZQ (32 μM) for 48 h. During this period, worms were 
analyzed and monitored under an inverted optical microscope (DM-500, Leica), to 
evaluate and monitor the motility and viability of the worms, and morphological 
changes in eggs of the two parasite strains studied in this work. For negative control 
III – Praziquantel-resistance in S. mansoni: morphological analysis of resistant and susceptible strains 
72 
 
of each group, worms were kept in RPMI-1640 drug free medium, under the same 
conditions. 
3.4.  Scanning electron microscopy 
To evaluate tegumental morphologic changes in both strains of S. mansoni after ex 
vivo exposure to PZQ, adult worms were analyzed using SEM according to [30, 36, 
37]. Briefly, worms were incubated at 37 ºC in a CO2 atmosphere (5%) for 24 h. After 
incubation, the parasites were washed with 0.1 M of Sodium Cacodylate buffer pH 7.2 
(for 1 h, changing the solution every 15 min), fixed in 2.5% Glutaraldehyde (pH 7.4) 
(Merck, Darmstadt, Germany) for 24 h and then fixed in 1% of Osmium Tetroxide for 1 
h. Specimens were dehydrated in increasing concentrations of Ethanol (50%, 70%, 
80%, 90%, 95% and 100%) for 30 min each, dried in a critical point dryer, mounted on 
stubs, metalized with gold particles using Sputter Coater and finally analyzed and 
photographed using an ultra-scanning electron microscope (Jeol-JSM-820). 
3.5.  Ethics statement 
This research project was reviewed and approved by the Ethics Committee and Animal 
Welfare, Faculty of Veterinary Medicine, UL (Ref. 0421/2013). Animals were kept and 
handled in accordance with National and European legislation (DL 276/2001 and DL 
314/2003; 2010/63/EU adopted on 22nd September 2010), with regard to animal 
protection and welfare, and all procedures were performed according to National and 
European legislation. The anesthetics and other techniques were used to reduce the 
pain and adverse effect of animal. 
3.6.  Statistical analysis 
Results were expressed as mean ± SD. Data were statistically analyzed using the IBM 
SPSS Statistics software version 20.0 for Windows. Kolmogorov-Smirnov (Lilliefors 
significance correction) and Shapiro-Wilk tests were used to analyze data normality 
and Levene’s test used to test homogeneity of variance. A t-test for independent 
samples was used to compare the average size of the eggs and lateral spines between 
susceptible and resistant strains, and Mann-Whitney (MW) test, to test whether there 
was difference between the ratios of lateral spines/eggs on the two strains studied. 
The level of significance was set at p < 0.05.  
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4. Results 
4.1. Ex vivo effect of Praziquantel on S. mansoni PZQ-resistant and 
PZQ-susceptible strains 
The viability of the adult worms was analyzed during ex vivo incubation with a 
concentration of 32 μM of PZQ for a 48 h period. We observed that the viability of adult 
worms resistant to PZQ and treated with this drug was similar to the negative resistant 
control group (resistant worms kept in RPMI-1640 drug free medium), in which all 
individuals were alive after the incubation period. We noticed that upon exposure to 
PZQ, adult worms from the resistant strain retracted, showed muscle contraction, 
reduction of movements (Figure III-2A-B) and, by the end of the incubation period, 
regaining motility (Figure III-2C), in comparison to the control group (Figure III-2D-F). 
Still, the worms remained alive and, after removal of the medium containing PZQ, they 
gradually regained full motility. 
 
Figure III-2. Monitoring of S. mansoni resistant strain adult worms submitted to 32 μM of PZQ 
during 48 h. (A) Adult worms from the resistant strain exposed to PZQ, showing muscle contraction 
and reduction of movements, 6 h after PZQ-exposure; (B) Adult worms from the resistant strain exposed 
to PZQ, showing muscle contraction and little movements (24 h after drug exposure); (C) Adult worms 
from the resistant strain exposed to PZQ, began to gain some motility by the end of the incubation period 
(48 h); (D) Adult worms from the resistant strain not exposed to PZQ (negative control group - resistant 
worms kept in RPMI-1640 medium with no addition of the drug), 6 h of incubation period; (E) Adult 
worms from the resistant strain not exposed to PZQ (negative control group - resistant worms kept in 
RPMI-1640 medium with no addition of the drug), 24 h of incubation period; (F) Adult worms from the 
resistant strain not exposed to PZQ (negative control group - resistant worms kept in RPMI-1640 
medium with no addition of the drug), at the end of the incubation period (48 h). 
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For susceptible parasites, where most of the worms were dead after drug addition, the 
viability was much lower compared to the negative susceptible control group 
(susceptible worms kept in RPMI-1640 drug free medium) and the treated-resistant 
parasite group. Susceptible strain parasites were more contracted (Figure III-3A) than 
those from the resistant isolate submitted to the same PZQ dose (Figure III-2A). After 
exposure to the drug, PZQ-susceptible adult worms retracted, showed muscle 
contraction, and reduction of movements (Figure III-3A), in comparison to the control 
group (Figure III-3C-D), and died after 24 h of incubation period (Figure III-3B). After 
removal of the medium containing PZQ, they did not recover motility, contrary to what 
happened with resistant strain parasites that gradually regained motility. 
 
Figure III-3. Monitoring of S. mansoni susceptible strain adult worms submitted to 32 μM of PZQ 
during 48 h. (A) Adult worms from the susceptible strain exposed to PZQ, showing muscle contraction 
and reduction of movements, 6 h after PZQ-exposure; (B) Adult worms from the susceptible strain dead 
after exposed to PZQ, 24 h after exposure; (C) Adult worms from the susceptible strain not exposed to 
PZQ (negative control group - susceptible worms kept in RPMI-1640 medium with no addition of the 
drug), 6 h of incubation period; (D) Adult worms from the susceptible strain not exposed to PZQ (negative 
control group - susceptible worms kept in RPMI-1640 medium with no addition of the drug), 24 h of 
incubation period. 
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Figure III-4. Morphological difference between eggs from resistant strain and susceptible strain. 
(A) Eggs from resistant strain parasites, showing morphology alterations, smaller size and smaller lateral 
spines (10x); (B) Eggs from resistant strain, in a bigger scale, showing morphology alterations, smaller 
size, and smaller lateral spines (40x); (C) Eggs from susceptible strain parasites, showing normal 
morphology (10x); (D) Eggs from susceptible strain parasites, showing normal morphology, in a bigger 
scale (40x). 
 
Regarding the egg morphology, it was different between PZQ-resistant and PZQ-
susceptible stains (Figure III-4). Eggs from resistant parasite females (Figure III-4A-B, 
n = 7) were smaller (p < 0.05) when compared to those from the susceptible strain 
(Figure III-4C-D, n = 7; Figure III-5 and Table III-1). Furthermore, we found statistical 
significant differences in the size of the lateral spine of the eggs, those from resistant 
strain females had smaller (p < 0.05) and thicker lateral spines than those of 
susceptible worms (Figure III-5 and Table III-1). Moreover, the lateral spine of the eggs 
from resistant strain had the terminal portion less salient and acute, compared to the 
susceptible strain (Figure III-4). In order to confirm that the observed differences in 
lateral spine size were not a simple consequence of smaller size of the egg in resistant 
worms, the ratio between lateral spine and egg sizes was determined for resistant 
strain and susceptible strain (Table III-1). When the ratio of the two strains were 
compared, we found a significant difference (p < 0.05) between them, which means 
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that the difference observed in the size of the lateral spine is not only a consequence 
of smaller size of the eggs but perhaps of an alteration in their morphology. These 
interesting findings need to be explored, since they might have important 
repercussions on pathological and symptomatology effects induced by this strain. 
 
Figure III-5. Difference in egg morphology of S. mansoni resistant strain and susceptible strain. 
Gray bars – measurements of eggs and lateral spines from susceptible strain worms; Black bars – 
measurements of eggs and lateral spines from resistant strain worms. Data was presented as mean ± 
SD. Statistical analysis was performed by parametric t-test, for independent simples, whose level of 
significance was set at p < 0.05. *Indicates p < 0.05.  
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Table III-1. Difference in egg morphology (size of the eggs and lateral spines and ratio between 
them) of S. mansoni resistant and susceptible parasites (n = 7). SS – susceptible strain, RS – 
resistant strain. 
Egg morphology 
Size (μm) 
mean ± SD 
95% 
Confidence 
Limits 
p-value 
Susceptible strain eggs 
101.80 ± 
2.99 
99.03 – 104.57 
p < 0.05 
 (t-test) 
Resistant strain eggs 
75.60 ± 
8.98 
67.29 – 83.91 
Susceptible strain lateral spines 
32.78 ± 
2.75 
30.24 – 35.33 
p < 0.05  
(t-test) 
Resistant strain lateral spines 
20.26 ± 
4.73 
15.88 – 24.64 
Susceptible strain ratio (SS spine/SS egg) 
0.32 ± 
0.018 
0.30 – 0.34 
p < 0.05  
(MW test) 
Resistant strain ratio (RS spine/RS egg) 
0.27 ± 
0.036 
0.23 – 0.29 
 
4.2. Effect of Praziquantel on tegument of S. mansoni PZQ-resistant 
and PZQ-susceptible strains 
We analyzed the presence of tegumental alterations in S. mansoni PZQ-resistant 
strain adult worms and in the parental PZQ-susceptible strain upon addition of 0.3 μM 
PZQ during 3 h, using SEM. Significant changes were only observed in male and 
female worms of the susceptible strain. In susceptible males not exposed to PZQ, the 
oral and ventral sucker (Figure III-6A) and body surface (Figure III-6B-C) did not show 
any changes, while males exposed to the same drug presented changes in acetabular 
sucker (Figure III-7A), tegument peeling (Figure III-7B), and destruction of tubercles 
and spines (Figure III-7C-D).  
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Figure III-6. Scanning electron microscopy of S. mansoni PZQ-susceptible strain. (A-C) 
Susceptible strain adult males of control group kept in RPMI-1640 drug free medium for 3 h, showing 
normal morphology of the tegument, and oral and ventral suckers; (D-F) Susceptible strain adult females 
of control group kept in RPMI-1640 drug free medium for 3 h, showing normal morphology of the 
tegument, and oral and ventral suckers. Image magnifications: (A) 180x 10 kV ________100 μm; (B) 
900x 10 kV ________10 μm; (C) 800x 10 kV ________10 μm; (D) 500x 10 kV ________10 μm; (E) 
1200x 10 kV ________10 μm; (F) 3300x 10 kV ________10 μm. 
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Figure III-7. Scanning electron microscopy of S. mansoni PZQ-susceptible strain adult males 
after exposure to 0.3 μM of PZQ for 3 h. (A) Susceptible strain adult males upon exposure to PZQ, 
presenting changes in acetabular suckers; (B) Tegument peeling; (C-D) Destruction of tubercles and 
spines. Red arrows indicate alterations. Image magnifications: (A) 300x 10 kV ________100 μm; (B) 
1200x 10 kV ________10 μm; (C) 800x 10 kV ________10 μm; (D) 850x 10 kV ________10 μm. 
 
Susceptible strain females not exposed to PZQ showed normal morphology of ventral 
and oral suckers (Figure III-6D) and normal morphology of the body surface (Figure 
III-6E-F), but when exposed to the drug, presented muscle contraction and 
corrugations (Figure III-8A-C). Furthermore, they showed alterations in the oral sucker 
(Figure III-8D) and peeling of some tegumental regions (Figure III-8E-F).  
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Figure III-8. Scanning electron microscopy of S. mansoni PZQ-susceptible strain adult females 
after exposure to 0.3 μM of PZQ for 3 h. (A-C) Susceptible strain adult females upon exposure to 
PZQ, showing muscle contraction and corrugations; (D) Alterations in oral sucker; (E-F) Peeling of some 
tegumental regions. Red arrows indicate alterations. Image magnifications: (A) 170x 10 kV 
________100 μm; (B) 110x 10 kV ________100 μm; (C) 1000x 10 kV ________10 μm; (D) 500x 10 kV 
________10 μm; (E) 900x 10 kV ________10 μm; (F) - 950x 10 kV ________10 μm. 
 
Tegumental alterations induced by PZQ were not so significant in the resistant strain, 
when compared to the susceptible strain. As expected, the control group of resistant 
males did not show any tegumental alterations, showing normal morphology of the oral 
and ventral suckers (Figure III-9A-B) and tegument (Figure III-9C-F). When exposed 
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to PZQ, those worms presented small alterations in some areas, such as changes in 
oral and ventral suckers (Figure III-10A-C), and little alterations in the body surface, 
with losses of tubercles and spines (Figure III-10D-F).  
 
Figure III-9. Scanning electron microscopy of S. mansoni PZQ-resistant strain adult males of 
control group kept in RPMI-1640 drug free medium for 3 h. (A-B) Resistant strain adult males kept 
in RPMI-1640 drug free medium, showing normal morphology of the oral and ventral suckers; (C-F) 
Normal morphology of the tegument. Image magnifications: (A) 70x 10 kV ________100 μm; (B) 170x 
10 kV ________100 μm; (C) 1200x 10 kV ________10 μm; (D) 950x 10 kV ________10 μm; (E) 2200x 
10 kV ________10 μm; (F) 850x 10 kV ________10 μm. 
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Figure III-10. Scanning electron microscopy of S. mansoni PZQ-resistant strain adult males after 
exposure to 0.3 μM of PZQ for 3 h. (A-C) Resistant strain adult males upon exposure to PZQ, 
presenting small changes in oral and ventral suckers; (D-F) Losses of tubercles and spines. Red arrows 
indicate alterations. Image magnifications: (A) 90x 10 kV ________100 μm; (B) 250x 10 kV 
________100 μm; (C) 160x 10 kV ________100 μm; (D) 550x 10 kV ________10 μm; (E) 600x 10 kV 
________10 μm; (F) 350x 10 kV ________100 μm. 
 
Similarly female resistant worms control group did not present any tegumental 
damages, neither in oral and ventral suckers (Figure III-11A-B), nor in the tegument 
surface (Figure III-11C-D). Upon drug exposure, those worms only showed very few 
alterations, namely, some morphological changes in the oral sucker (Figure III-12A), 
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some light peeling in the worm ventral region (Figure III-12B), and alterations in some 
tegumental areas (Figure III-12C-D). 
 
Figure III-11. Scanning electron microscopy of S. mansoni PZQ-resistant strain adult females of 
control group kept in RPMI-1640 drug free medium for 3 h. (A-B) Resistant strain adult females kept 
in RPMI-1640 drug free medium, showing normal morphology of the oral and ventral suckers; (C-D) 
Normal morphology of the tegument. Image magnifications: (A) 450x 10 kV ________10  μm; (B) 2000x 
10 kV ________10 μm; (C) 950x 10 kV ________10 μm; (D) 2500x 10 kV ________10 μm. 
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Figure III-12. Scanning electron microscopy of S. mansoni PZQ-resistant strain adult females 
after exposure to 0.3 μM of PZQ for 3 h. (A) Resistant strain adult females upon exposure to PZQ, 
presenting changes in oral suckers; (B) Light peeling in the worm ventral region; (C-D) Alterations in 
some tegumental areas. Red arrows indicate alterations. Image magnifications: (A) 220x 10 kV 
________100 μm; (B) 550x 10 kV ________10 μm; (C) 160x 10 kV ________100 μm; (D) 900x 10 kV 
________10 μm. 
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5. Discussion 
In past years, several studies have been performed in order to demonstrate that 
resistance/tolerance to PZQ may occur and is more than hypothetical [26-29]. Our 
group in particular had selected, by stepwise drug pressure, a S. mansoni strain that 
is isogenic to its parental fully susceptible counterpart, except for genetic determinants 
accounting for the PZQ-drug resistance phenotype, and phenotypically similar to the 
susceptible strain except in resistance [32]. In the present study, we took the 
advantage of the availability of these two strains of S. mansoni and performed a 
comparative assessment of morphological alterations that the ex vivo effect of PZQ 
can cause on S. mansoni PZQ-resistant parasites. Some authors [38, 39] have already 
performed studies with PZQ-resistant isolates obtained from an Egyptian and a 
Senegalese patient eggs, which were not cured by three therapeutic doses of PZQ, 
where they demonstrated that isolates from resistant infections were less susceptible 
to PZQ-induced tegumental damage ex vivo [38] and PZQ-resistant isolates may be 
more pathogenic in mice than the susceptible ones [39]. However, as far as we know, 
this is the first report in which the ex vivo effect of PZQ on the morphological 
characteristics of a resistant strain of S. mansoni can be compared with its parental 
susceptible strain. 
Parameters, such as motor activity, eggs morphology and tegumental changes, are 
often evaluated as indicators of biological activity in studies using schistosome species 
[38, 40-48], hence we evaluate these parameters in order to assess the effect of PZQ 
on adult S. mansoni PZQ-resistant and PZQ-susceptible worms’ survival and fitness. 
Our study shows that resistant strain worms have less muscle contraction and 
movements after exposure to PZQ than susceptible isolates. This complies with 
studies suggesting that contraction of somatic musculature is a marked effect of 
addition of PZQ to schistosomes ex vivo [38], and that worms resistant to PZQ in vivo 
have significantly reduced contractile responses to PZQ ex vivo [27]. It is also evident 
that, after removal of the medium containing the drug, resistant worms recover motility, 
unlike susceptible worms, where the majority of which are dead. 
The tegument is a very important organ for schistosomes, for many reasons: it is 
important for the survival of the worms in the host [49-51], protecting the parasite 
against the action of the host’s immune system, absorbing nutrients and molecules 
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and participating in synthesis of some proteins [52-54]. Some studies carried out many 
years ago, tried to clarify the action mechanisms of drugs used in schistosomiasis 
treatment. It has been shown that, worms subjected to PZQ, have vacuolization of the 
tegument and disruption of the apical tegumental layer [55]. Female worms present 
tegumental damage, such as, tegument and sub-tegument vacuolization and tegument 
and musculature destruction, while male worms show more pronounced and extensive 
surface alterations, which include surface bleeding, swellings, wrinkling, constrictions 
and surface lesions, particularly on the spined tubercles [56]. 
As shown by William and colleagues [38], our findings demonstrate that tegumental 
damage caused by the ex vivo effect of PZQ is much less evident in resistant strain 
adult worms than in the susceptible strain. Contrarily to what occurs in resistant 
parasites, in which PZQ does not seem to cause major damage, males of the 
susceptible strain present tegument peeling, tubercle and spine destruction and 
vesicles around the tubercles while females display peeling and wrinkling of the 
tegument and destruction of oral and acetabular suckers. These suggest that there 
might be a difference in the resistant strain tegument composition that may render the 
worms less responsiveness to PZQ. Therefore, it will be very interesting to perform a 
more in-depth study of the resistant strain tegument, using for instance the 
transmission electron microscopy in order to analyze the ultrastructure of the resistant 
strain tegument, allowing to see if PZQ resistance might in any way influence pathology 
symptomology, since one of the hallmark effects of PZQ on schistosomes ex vivo is 
the disruption of surface tegument [38]. It is important to notice that susceptible strain 
females presented much less damage than males. This observation is in agreement 
to the findings described in the previous Chapter where females appeared more 
tolerant to PZQ [32]. In the resistant strain, damages on both males and females were 
so small that it is far more difficult to make a similar comparison. 
It has been stated in literature that the oviposition of S. mansoni during in vitro culture 
of adult worm show three very distinct phases in the kinetics of oviposition: an initial 
phase with low egg production, a period of maximum oviposition and finally a gradual 
reduction in the number of eggs during the last phases of culture [57]. Liang and 
colleagues [39] demonstrated that mice infected with PZQ-resistant isolates shed more 
eggs in their feces than those carrying drug-susceptible parasites and mice infected 
with any of the resistant isolates also had larger numbers of eggs in their tissues. Mice 
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infected with our PZQ-resistant strain shed more eggs than those infected by the 
counterpart susceptible strain [Personal observation]. This is important because if 
there is a change in the biological characteristics of schistosomes associated with the 
development of resistance to PZQ, it could affect the transmission and pathology of 
the disease they cause [39]. 
Another interesting finding observed in this study is that resistant strain eggs have 
different morphology, with smaller size and a smaller lateral spine (less salient and 
acute) in comparison with eggs from susceptible strain, which may have repercussions 
in the pathology of the disease, once the eggs are the major cause of pathology in 
schistosomiasis [58]. We have observed that some mice infected with the PZQ-
resistant strain used here presented some neurological manifestations including 
deviation of the head, tendency to roll over on stimulation, ataxia, and convulsions, 
very similar to what is usually seen in mice affected with cerebral malaria [59]. Based 
on this, it is not unreasonable to speculate that resistant strain parasites might have 
altered tissue tropism, namely, a higher tropism for brain or spinal cord, which may 
potentiate the development of neurological manifestations. Clearly, further studies on 
mice infected with PZQ-resistant isolates are required to confirm this hypothesis. 
In conclusion, we compared morphological characteristics of S. mansoni PZQ-resistant 
and PZQ-susceptible strains upon addition of this drug ex vivo. It was demonstrated 
that the resistant strain presents i) less muscular contractions, ii) less tegumental 
damage, iii) more viability,  and iv) recovering motility when the drug is removed, 
indicating fully active life after a PZQ treatment is ceased. The resistant strain 
demonstrated different egg morphology when compared with susceptible strain. Those 
are important findings since any biological changes can produce relevant alterations 
in the transmission and pathology of diseases. Comparing two strains that only differ 
in resistance characteristics is an important step in the study of schistosomiasis as it 
guarantees that the differences observed between the two strains are closely related 
to resistance. Increase tolerance/resistance to PZQ in in vivo experiments is an 
obvious fact and studies should be performed to clarify the mechanisms associated 
with it. This study certainly opens doors for further in-depth S. mansoni drug resistance 
studies.  
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1. Abstract 
The extensive use of PZQ, the only drug available to treat schistosomiasis, has brought 
concern about the emergence of PZQ-resistance/tolerance by Schistosoma spp., thus 
reaffirming an urge for the development of new treatment alternatives. Studies of 
Schistosoma spp. genome, transcriptome and proteome are crucial to better 
understand this situation. By stepwise drug pressure from a fully susceptible parasite 
strain, our group selected a S. mansoni variant strain stably resistant to PZQ and 
isogenic to its fully susceptible parental counterpart, except for the genetic 
determinants of PZQ-resistance phenotype. Based on this, the objective of this study 
was to compare the proteomes of both strains, identifying proteins from male and 
female adult worms of PZQ-resistant and PZQ-susceptible strains, exposed and not 
exposed to PZQ, which were separated by high-resolution two-dimensional 
electrophoresis and sequenced by high throughput LC-MS/MS. This study identified 
60 S. mansoni proteins, some of which differentially expressed in either strain. This 
information represents substantial progress towards deciphering the worm proteome. 
Furthermore, these data may constitute an informative source for further investigations 
into PZQ-resistance and increase the possibility of identifying proteins related to this 
condition, possibly contributing to avoid or decrease the likelihood of development and 
spread of PZQ-resistance.  
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2. Introduction 
Schistosomiasis is one of the most important infectious parasitic diseases mainly in 
sub-Saharan Africa [1, 2]. Despite many efforts to control its transmission [3-5], 
essentially after the introduction of a chemotherapeutic treatment in 1980s, the disease 
is still highly prevalent [6]. Nowadays, this control is based on PZQ the only drug 
available for chemotherapy [7]. Treatment with PZQ is effective and inexpensive [7], 
but frequent schistosome reinfection occurs in endemic areas and may cause 
irreversible damages to the liver, kidneys, or urinary tract [8]. Because of its high 
prevalence, schistosomiasis has earned a Category II disease, ranking next to malaria, 
for importance as a target tropical disease by the World Health Organization Special 
Program for Research and Training in Tropical Diseases [8]. 
Although the impact of schistosomiasis could be dramatically reduced by improvement 
in education and sanitation for humans and elimination of the intermediate host snails, 
such methods are not sufficient to control or eradicate this parasitosis. In the absence 
of vaccines, the control of this disease relies on chemotherapy to ease symptoms and 
reduce transmission. The increasing reliance on mass PZQ administration programs 
has exerted selective pressure on parasite population and PZQ-resistance/loss of 
susceptibility is being described by different investigators [9-11]. With no alternative 
drugs or vaccines, the fight against schistosomiasis could become a huge battle [12]. 
Identification of proteins is very important for understanding how schistosomes 
regulate host immune systems to establish chronic infections and also elucidate other 
aspects of parasite-host interaction [8]. Furthermore, a comprehensive deciphering of 
the schistosome genome, transcriptome, and proteome has become increasingly 
central for understanding the complex parasite-host interplay [13, 14]. Therefore, such 
information can be expected to facilitate the discovery of vaccines and new therapeutic 
drug targets, as well as new diagnostic reagents for schistosomiasis control [8, 13, 14], 
and may aid the development of protein probes for selective and sensitive diagnosis 
of schistosomiasis [15]. 
Proteomics approaches encompass the most efficient and powerful tools for 
identification of protein complexes [16-18] and have been widely used to decipher the 
proteome of parasites such as nematodes [19] and trematodes [20-27]. For 
Schistosoma spp., the proteome has been studied in many developmental life stages, 
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including schistosomula [28, 29], cercariae [29-31], egg [29, 32] and adult worm [29, 
33-36]. But to our knowledge, S. mansoni PZQ-resistant strain proteome has not been 
yet reported and a schistosomiasis mansoni coherent screening for proteins related to 
PZQ-resistance is still necessary. Understanding the development of PZQ-resistance 
in S. mansoni is crucial to prolong the efficacy of the current drug and develop markers 
for monitoring drug resistance. It would also be beneficial in the design of new 
chemotherapeutic agents to overcome or prevent resistance, and in the identification 
of new drug targets. 
As described in the Chapter II, our research group recently developed a resistant strain 
of S. mansoni that tolerates up to 1,200 mg PZQ/kg of mouse body weight. This S. 
mansoni variant strain was selected from a fully susceptible parasite strain, by 
stepwise drug pressure, and is isogenic, except for the genetic determinants of PZQ-
resistance phenotypes, and significantly different of the counterpart S. mansoni 
susceptible strain [37]. As such, this S. mansoni PZQ-resistant strain represents a 
distinct and valuable model for the study of PZQ-resistance. 
The present study intended to analyze, for the first time, the proteome of S. mansoni 
PZQ-resistant adult worms and compare it with its parental fully susceptible strain, 
using a high throughput LC-MS/MS identification. Therefore, this study could possibly 
represent a substantial progress toward deciphering the worm proteome, and may 
constitute an informative source for further investigations into PZQ-resistance, 
increasing the possibility of avoid or decrease the likelihood of development and 
spread of PZQ-resistance.  
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3. Material and Methods 
3.1. Parasite samples 
Two different parasite isolates were used in this study, the S. mansoni BH PZQ-
susceptible strain (SS) and a stable PZQ-resistant strain (RS) obtained from the same 
BH strain as described in Chapter II [37]. These two parasite strains are routinely kept 
in their intermediate host B. glabrata snails at IHMT/UNL. 
Mus musculus CD1 line male mice was chosen as the animal model for S. mansoni 
infection, because it is a good host for this parasite mimicking the S. mansoni human 
infection [38]. Mice infection occurred by natural transdermal penetration of cercariae, 
by exposing mice tails to about 100 cercariae of S. mansoni each. 
Eight to ten-weeks adult worms were recovered by perfusion of the hepatic portal 
system and mesenteric veins, according to [39], and washed twice in RPMI-1640 
medium (Sigma-Aldrich), to remove contaminating hair and blood clots. 
It was analyzed males and females in separate, not exposed and exposed to PZQ, for 
RS and SS. Regarding to the groups of adult worms exposed to PZQ (EPZQ), after 
collecting, the parasites were transferred to 24-well culture plates containing RPMI-
1640 culture medium, 200 mM L-glutamine, 10 mM HEPES, 24 mM of NaHCO3, 
10,000 UI of Penicillin and 10 mg/mL of Streptomycin, from Sigma-Aldrich, pH 7 and 
supplemented with 15% fetal bovine serum. Adult worms of the parasite were added 
on each well for each studied group for PZQ treatment: 1) PZQ-susceptible males 
(SM); 2) PZQ-susceptible females (SF); 3) PZQ-resistant males (RM), and 4) PZQ-
resistant females (RF). Adult parasites were treated in culture, with 0.3 μM of PZQ 
during 24 h and then washed twice with saline solution to clean any traces of culture 
medium and stored in Trizol (Invitrogen, Carlsbad, California, USA) at -80 ºC, for 
posterior protein extraction. For the groups of adult worms not exposed to PZQ 
(NEPZQ), worms were kept in RPMI-1640 medium with no addition of drug, then 
washed twice with saline solution to clean any traces of culture medium and also stored 
in Trizol (Invitrogen, Carlsbad, California, USA) at -80 ºC, for posterior protein 
extraction. Accordingly, the experimental set up consisted of eight sample groups, four 
for parasites not exposed to PZQ (RM-NEPZQ, RF-NEPZQ, SM-NEPZQ and SF-
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NEPZQ) and four for parasites exposed to PZQ (RM-EPZQ, RF-EPZQ, SM-EPZQ and 
SF-EPZQ).  
3.2. Preparation of protein extracts 
Schistosoma mansoni adult worm protein extracts were obtained using Trizol 
(Invitrogen, Carlsbad, California, USA) protocol, according to the manufacturer’s 
instructions. Briefly, the parasites were lysed and homogenized directly in Trizol 
reagent at room temperature. The homogenized samples were incubated at room 
temperature to permit complete dissociation of the nucleoprotein complex. After 
homogenization, we proceeded to separation phase, adding Chloroform and 
centrifugation of samples. The aqueous phase was removed and the interphase and 
organic phenol-chloroform phase was used for protein isolation procedure. Next, 
Isopropanol precipitation was performed and the pellet was solubilized in SBI buffer [7 
M Urea, 2 M Thiourea, 15 mM 1,2-diheptanoyl-snglycero-3-phosphatidylcholine, 0.5% 
Triton X-100, 20 mM Dithiotheitol (DTT) and Complete Mini Protease Inhibitor Cocktail 
Tablets], according to [40], and stored at -80 ºC until use. 
Protein concentration in protein extracts was measured by Bradford assay [41] and the 
quality of the extract was verified in 12% uniform SDS-Polyacrylamide gel 
electrophoresis (PAGE). 
3.3. Two-dimensional electrophoresis 
Each experiment with two-dimensional electrophoresis (2-DE) gels was performed in 
triplicate with 240 μg of proteins, for each group. To prepare samples for 2-DE, protein 
samples in the mentioned concentration were diluted in rehydration solution containing 
7 M Urea, 2 M Thiourea, 4% CHAPS (3-[3-(cholamidopropyl)dimethylammonio]-1-
propanesulfonate), 0.5% IPG buffer, 1% DTT (Sigma), and 0.002% Bromophenol blue 
(Sigma). The rehydration was carried out passively overnight during 12 h in a 13 cm, 
pH 3-10 strip (Immobiline Drystrips, GE Healthcare). The strips were then applied on 
an Ettan IPGphor 3 (GE Healthcare) system, for protein separation by isoelectric 
focusing (IEF) following a typical IEF protocol, which involved three focusing steps at 
a constant 50 μA/strip: 3 h gradient to 3,500 V, 3 h at 3,500 V and finally 64,000 V h, 
until the end. 
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After focusing, the strips containing protein were reduced in an equilibration solution 
(50 M Tris HCl, pH 8.8, 6 M Urea, 20% Glycerol, 2% SDS) containing 2% DTT, and 
then alkylated in the same solution containing 2.5% Iodoacetamide (Sigma). The 
Immobilized pH gradient (IPG) strips and molecular weight standards were then 
transferred to the top of 12% uniform SDS-PAGE gels and sealed with 0.5% agarose. 
The second dimension was carried out using a Protein Plus Dodeca cell system (Bio-
Rad) under an initial current of 15 mA/gel for 15 min, followed by increasing the current 
to 50 mA/gel until the end of the run (the dye front reached the bottom of the gel). 
For 2-DE experiments, at least three replica of two dimensional polyacrylamide gel 
electrophoresis were performed for each group, confirming the reproducibility of the 
experimental procedure. Gels were fixed in 40% Methanol/10% Acetic Acid solution 
and stained with Coomassie Brilliant Blue R-350 (GE Healthcare). The spots were 
normalized and evaluated by the software ImageMaster 2D Platinum 7.0 (GE 
Healthcare).  
3.4. In-gel digestion and peptide preparation for mass spectrometry 
analysis 
The selected protein spots from the three replicate SDS-PAGE gels of each group 
were manually excised, distained, reduced, alkylated and digested in gel with Trypsin 
(Promega, Fitchburg, Wisconsin, USA). First, spots were washed in Milli-Q water, and 
then distained in a distaining solution containing 50% Methanol/2.5% Acetic Acid in 
purified water for 2 h at room temperature. This step was repeated until clear of blue 
stain. The gel fragments were incubated in 100% Acetonitrile (ACN) with occasional 
vortexing, until gel pieces became white and shrank. Then, the solution was removed 
and spots were completely dried, and ready for digestion. The in-gel digestion with 
Trypsin-modified sequencing-grade reagents (Promega) was done according to [42]. 
Briefly, protein digestion was conducted at 37 ºC overnight. After the incubation, the 
supernatant was transferred to a clean tube and 30 μL of 5% Formic Acid (FA)/60% 
ACN were added to gel spots for the extraction of tryptic peptides. This procedure was 
performed 2 x 30 min under constant agitation. The supernatant was pooled to the 
respective tube containing the initial peptide solution. This solution was dried in a 
SpeedVac (Thermo Scientific) and the peptides were re-suspended in 8 μL of 0.1% 
FA. The peptides were desalted in reverse phase micro-columns Zip-Tip C18 
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(Millipore), according to manufacturer’s instructions. Peptides were dried again and re-
suspended in 50% ACN/ 0.1% Trifluoracetic Acid (TFA) solution. 
3.5. Peptide analysis by LC-MS/MS and protein identification 
The digested peptides were analyzed by LC-MS/MS using a nano-LC system (EASY-
nLC II, Thermo Scientific), coupled online to a hybrid mass spectrometer ion trap linear-
Orbitrap (LTQ Orbitrap Velos, Thermo Scientific) using an ion nanospray source, 
namely, Nano-Flex II nanospray (Thermo Scientific). The samples were injected (10 
μL/min, 4 min) in a pre-column (C18, 100 μm DI x 2 cm, Thermo Scientific), and then 
eluted under flow of 300 nL/min using an elution gradient to a C18 column (10 cm × 75 
μm DI, 3 μm, 120 Å, Thermo Scientific). All LC-MS/MS data (in RAW format) were 
acquired using XCalibur software, version 2.0.7 (Thermo Fisher Scientific) and 
converted in .mgf files using MassMatrix MS Data File Conversion version 3.9. The 
analyzes were performed in scan mode in the range of 400-2000 m/z; positive mode; 
capillary voltage of 4500 V; nebulizer to 8.0 psi; drying gas at a flow of 5.0 L/min and 
at 220 ºC of evaporation temperature of the spray. 
The list of peptide and fragment mass values generated by the mass spectrometer for 
each spot were submitted to a MS/MS ion search using the Mascot 2.0 online search 
engine (Matrix-Science) to search the LC-MS/MS data against the NCBInr database 
Schistosoma_mansoni_NCBI_112014, November 2014. The database was 
downloaded and transferred to a searchable database for MS/MS data on an in-house 
Mascot server. The parameters used were: allowance of two tryptic miss cleavages, 
peptide mass tolerance of ±0.6 Da, fragment mass tolerance of ±0.2 Da, peptide 
charge +1, variable modifications of methionine (oxidation), and fixed modifications of 
cysteine (carbamidomethylation). To avoid random matches, only ions with individual 
score above of the indicated by the Mascot to identity or extensive homology (p < 0.05) 
were considered for protein identification. However, when the Mascot score was not 
significant, but the percentage coverage and root mean squared error (RMSE) were in 
the same range as those of proteins with a significant match, proteins were deemed 
identified if additional parameters, such as its calculated pI and Mw, were in agreement 
with those observed for the actual gel spot and the species matched was S. mansoni, 
according to [29]. 
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The molecular function and biological process were assigned for the proteins identified 
according to information obtained from the Gene Ontology (GO) database [43, 44]. 
The exact annotation for each protein was used in most cases. However, the catalytic 
activity category was used for all proteins with molecular function associated with 
(GTPase, hydrolase, isomerase, kinase, ligase, lyase, oxidoreductase, transcription 
and transferase activities). Binding category was used for all types of ligand identified 
(actin, ATP, Calcium, GTP, magnesium ion, metal ion, protein domain specific and 
nucleotide bindings). Furthermore, there was other molecular function categories 
classified such as chaperone, motor, regulation of muscle contraction, structural and 
transport. The proteins that had no associated known function were classified as 
“unknown”. 
3.6. Ethics statement 
This research project was reviewed and approved by the Ethics Committee and Animal 
Welfare, Faculty of Veterinary Medicine, UL (Ref. 0421/2013). Animals were 
maintained and handled in accordance with National and European legislation (DL 
276/2001 and DL 314/2003; 2010/63/EU adopted on 22nd September 2010), with 
regard to the protection and animal welfare, and all procedures were performed 
according to National and European legislation. The anesthetics and other techniques 
were used to reduce the pain and adverse effect of animal.  
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4. Results 
4.1. 2-DE separation of proteins from S. mansoni PZQ-resistant and 
PZQ-susceptible adult worms 
As said in the Material and Methods section of this Chapter, in total, eight protein 
extracts were analyzed: four from parasites not exposed to PZQ (NEPZQ) [resistant 
males and females (assigned as RM-NEPZQ and RF-NEPZQ, respectively), and 
susceptible males and females (assigned as SM-NEPZQ and SF-NEPZQ, 
respectively)] and another four samples from parasites exposed to PZQ (EPZQ) 
[resistant males and females (assigned as RM-EPZQ and RF-EPZQ, respectively), 
and susceptible males and females (assigned as SM-EPZQ and SF-EPZQ, 
respectively)]. All protein extracts presented high purity and good quality for posterior 
2-DE and mass spectrometry (MS) analysis (Figure IV-1). 
 
Figure IV-1. SDS-PAGE gel of the protein preparations, confirming the quality of the protein 
extracts studied. RM – Resistant males; SM – Susceptible males; RF – Resistant females; SF – 
Susceptible females; Mr – Molecular reference. 
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Analytical 2-DE gels were produced using 13 cm, pH 3-10NL strips and SDS-PAGE 
12%, stained by Coomassie Blue to reproducibly resolve protein spots in a broad pH 
range and molecular weight, and posteriorly compare the protein pattern of S. mansoni 
proteome from the two strains (PZQ-resistant and PZQ-susceptible) not exposed 
(Figure IV-2) and exposed to PZQ (Figure IV-3). 
 
Figure IV-2. Two-dimensional gel electrophoresis of protein samples from S. mansoni adult 
worms not exposed to PZQ using 13 cm, pH 3-10NL strips and SDS-PAGE 12%, stained by 
Coomassie Blue. A - SM-NEPZQ; B – RM-NEPZQ; C – SF-NEPZQ; D – RF-NEPZQ. Numbers identify 
the spots, which were analyzed and identified by MS. All the identified proteins are listed in Table IV-2. 
The figure shows one representative experiment of three replicates. 
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Figure IV-3. Two-dimensional gel electrophoresis of protein samples from S. mansoni adult 
worms exposed to PZQ using 13 cm, pH 3-10NL strips and SDS-PAGE 12%, stained by 
Coomassie Blue. A - SM-EPZQ; B – RM-EPZQ; C – SF-EPZQ; D – RF-EPZQ. Numbers identify the 
spots, which were analyzed and identified by MS. All the identified proteins are listed in Table IV-2. The 
figure shows one representative experiment of three replicates. 
2-DE maps constructed with Coomassie Blue-stained gels showed reasonably 
comparable numbers of spots in all the samples. In total 133 ± 14, 265 ± 20, 142 ± 8 
and 188 ± 34 spots were detected in proteins from RM-NEPZQ, RF-NEPZQ, SM-
NEPZQ and SF-NEPZQ, respectively (Table IV-1). For parasites exposed to PZQ, 203 
± 14, 133 ± 9, 220 ± 34 and 99 ± 19 spots were detected in RM-EPZQ, RF-EPZQ, SM-
EPZQ and SF-EPZQ, respectively (Table IV-1). It is worth noting that 2-DE gels from 
RF-NEPZQ, RM-EPZQ and SM-EPZQ contain larger numbers of protein spots 
compared to other samples. 
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Table IV-1. Summary comparison of the number of protein spots in the 2-DE maps for the eight 
different protein extracts analyzed. 
 
Not exposed to PZQ 
(NEPZQ) 
Exposed to PZQ  
(EPZQ) 
Samples RM RF SM SF RM RF SM SF 
Replica 1 145 243 151 150 215 124 242 80 
Replica 2 135 270 138 200 188 135 181 99 
Replica 3 118 281 136 215 207 141 237 117 
Mean ±  
SD 
133 ± 
14 
265 ± 
20 
142 ± 
8.0 
188 ± 
34 
203 ± 
14 
133 ± 
9.0 
220 ± 
34 
99 ± 
19.0 
4.2. LC-MS/MS analysis and protein identification 
The spots differentially expressed were excised from preparative gels of each sample, 
digested by Trypsin and identified by LC-MS/MS. For RM-NEPZQ 64 spots were 
successfully analyzed by LC-MS/MS, as well as 69 from RF-NEPZQ, 67 from SM-
NEPZQ, 68 from SF-NEPZQ, 68 from RM-EPZQ, 69 from RF-EPZQ, 67 from SM-
EPZQ, and 66 spots from SF-EPZQ (Table IV-2). The MS/MS results were employed 
to search the database (NCBInr) by Mascot search engine, and the matched proteins 
are listed in Table IV-2. Some proteins were identified in only one individual spot, but 
on several occasions, more than one spot in a gel corresponded to the same protein 
or better, same isoforms (Figure IV-2, Figure IV-3 and Table IV-2). 
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Table IV-2. Proteins and spots identified in the samples from parasites not exposed and exposed 
to PZQ. 
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Table IV-2 (Continuation 1). Proteins and spots identified in the samples from parasites not 
exposed and exposed to PZQ. 
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Table IV-2 (Continuation 2). Proteins and spots identified in the samples from parasites not 
exposed and exposed to PZQ. 
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Sixty individual protein species were identified on samples from parasites not exposed 
to PZQ, of which 45 were present in RM-NEPZQ, 52 in RF-NEPZQ, 45 in SM-NEPZQ 
and 47 proteins in SF-NEPZQ (Table IV-2). In this group of NEPZQ parasites, 35 
proteins were common to all the four protein extracts, eight occurred only in resistant 
worms, eight only in susceptible worms, four in female parasites, and three were only 
present in resistant females. Interestingly, two proteins that have shown to be common 
in RM-NEPZQ, RF-NEPZQ and SM-NEPZQ preparations, namely Serine/Threonine 
phosphatase and Troponin I, did not appear in SF-NEPZQ (Figure IV-4, Figure IV-5A 
and Table IV-3). 
 
Figure IV-4. Number of unique and shared proteins identified between and among the protein 
preparations from parasites not exposed and exposed to PZQ. 
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The total number of proteins identified was reduced to 55 proteins on the protein 
extracts from parasites exposed to PZQ. Forty-eight of those proteins were present in 
RM-EPZQ, 52 in RF-EPZQ, 45 in SM-EPZQ, and 46 in SF-EPZQ (Table IV-2). Forty-
two proteins appeared to be common to all the four proteins preparations of EPZQ 
parasites. In addition, four proteins were present only in resistant strain, one in 
susceptible strain, three were exclusive of female parasites, two proteins were present 
only in male parasites and three were only in resistant females. Five proteins that were 
present on parasites not exposed to PZQ, namely, collagen alpha chain, dopamine 
transporter, twister (putative), ubiquitin-specific peptidase 30 (C19 family), and 
Smp_162220, did not appear here (Figure IV-4, Figure IV-5B and Table IV-3). 
 
Figure IV-5. Venn diagram showing the number shared proteins identified between and among 
the protein preparations from parasites. A) Not Exposed to PZQ; B) Exposed to PZQ. RS-♂: resistant 
strain males; RS-♀: resistant strain females; SS-♂: susceptible strain males; SS-♀: susceptible strain 
females. Common spots identified between and among the samples are represented overlapped by the 
circles. 
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Table IV-3. Specific proteins identified in each group analyzed.  
Worms Not exposed to PZQ (NEPZQ) Exposed to PZQ (EPZQ) 
Resistant 
strain 
Susceptible  
strain 
Resistant 
strain 
Susceptible 
strain 
Males   -Serine / threonine 
phosphatase; 
-Troponin I. 
 
-Serine / threonine 
phosphatase; 
-Troponin I. 
Females -Collagen alpha chain;  
-Cytosol 
aminopeptidase;  
-Inosine-5'-
monophosphate 
dehydrogenase;  
-Ubiquitin protein ligase 
E3a;  
 
*- Beta 1,3-
galactosyltransferase;  
*- Cathepsin L;  
*- Receptor for activated 
Protein Kinase C (PKC). 
-Collagen alpha chain;  
-Cytosol 
aminopeptidase;  
-Inosine-5'-
monophosphate 
dehydrogenase;  
-Ubiquitin protein ligase 
E3a; 
 
 
 
-Cytosol 
aminopeptidase;  
-Inosine-5'-
monophosphate 
dehydrogenase;  
-Ubiquitin protein ligase 
E3a; 
 
*- Beta 1,3-
galactosyltransferase;  
*- Cathepsin L;  
*- Receptor for activated 
Protein Kinase C (PKC). 
 
-Cytosol 
aminopeptidase;  
-Inosine-5'-
monophosphate 
dehydrogenase;  
-Ubiquitin protein 
ligase E3a; 
Both -Galactokinase; 
-Ornithine 
aminotransferase; 
-Rab6-interacting protein 
2 (ERC protein 1); 
-Transducin beta-like; 
-Dopamine transporter;  
-Twister, putative; 
-Ubiquitin-specific 
peptidase 30 (C19 
family); 
-Smp_162220.  
-ATP-dependent 
transporter; 
-Lysine tRNA ligase; 
-Phosphopyruvate 
hydratase; 
-Protein kinase; 
-RNA m5u 
methyltransferase; 
-Suppressor of actin 
(Sac); 
-Smp_018790; 
-Smp_161260.  
-Galactokinase; 
-Ornithine 
aminotransferase; 
-Rab6-interacting protein 
2 (ERC protein 1); 
-Transducin beta-like. 
 
-Phosphopyruvate 
hydratase. 
 
 
 
 
*Proteins present only in resistant females. 
4.3. Molecular function of identified proteins 
The proteins identified by MS/MS, and summarized in Table IV-2, were categorized by 
their molecular function, according to information obtained from the GO database 
(Table IV-4), as described in the Material and Methods section. When proteins had 
another function annotation, they were shown in brackets. The biological process and 
subcellular localization assigned to each protein in that database are also included in 
the Table IV-4. The results allowed the identification of proteins categorized as binding, 
catalytic, transport, regulation of muscle contraction, chaperone, motor, structural 
activities and proteins of unknown functions. Among the molecules identified as 
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binding proteins, most of them were ATP, nucleotide, protein and ion binding proteins. 
The proteins categorized correspond to a variety of biological processes, nevertheless 
most of them were glycolytic enzymes and proteins related to metabolic process. 
Regarding to the subcellular localization, the proteins identified were classified as 
cytoskeletal, cytosolic, nuclear, membrane proteins and some of them were located on 
extracellular matrix. Among them, the most abundantly identified were cytosolic 
proteins. There were fifteen and seven proteins whose biological process and 
subcellular localization, respectively, were not predicted (Table IV-4). 
Table IV-4. Proteins identified by their MS/MS and categorized by their molecular function 
according to information obtained from GO database.  
Molecular 
function 
Protein name Biological Process Subcellular 
localization 
Binding  
(19) 
   
-14-3-3 epsilon  - -Cytosol 
-14-3-3 protein homolog 1 - -Cytosol 
-14-3-3 protein homolog 2 - -Cytosol 
-Actin-1 (Motor, structural) - -Cytoskeleton 
-Actin-2 (Motor, structural) - -Cytoskeleton 
-Calponin -Actomyosin structure 
organization 
-Cytosol 
-Cytosol aminopeptidase -Metabolic process; 
proteolysis  
-Cytosol 
-DNA helicase -DNA replication -Nucleus 
-Dopamine transporter (Transport) -Transport -Membrane 
-Gelsolin - -Cytoskeleton 
-Heat shock 70 kDa protein homolog (Chaperone) -Stress response -Cytosol 
-Heat shock protein 70 (HSP 70) (Chaperone) -Stress response -Cytosol 
-Myosin regulatory light chain -Muscle contraction -Cytoskeleton 
-Receptor for activated Protein Kinase C (PKC) - - 
-Sortingnexin-related -Endocytosis -Membrane 
-Tegument antigen (Antigen SmA22.6) -Microtubule-based process -Membrane 
-Troponin I - -Cytosol 
-Uncharacterized protein, Smp_162220 (88% 
identity with SJCHGC07938 protein - S. 
japonicum) 
- - 
-Uncharacterized protein, Smp_171780 (95,2% 
identity with SPARC protein - S. haematobium) 
-Signal transduction -Extracellular 
matrix 
*Numbers in brackets indicate the amount of proteins with those certain functions. 
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Table IV-4 (Continuation 1). Proteins identified by their MS/MS and categorized by their molecular 
function according to information obtained from GO database.  
Molecular 
function 
Protein name Biological Process Subcellular 
localization 
Catalytic 
activity 
 (15) 
-Aldehyde dehydrogenase -Metabolic process -Cytosol 
-Beta 1,3-galactosyltransferase -Protein glycosylation -Membrane  
-Cathepsin L -Proteolysis - 
-Fructose bisphosphate aldolase -Glycolysis -Cytosol 
-Glutathione S-transferase 28 kDa  -Detoxification -Cytosol 
-Malate dehydrogenase  -Metabolic process -Cytosol 
-Phosphoglycerate mutase -Glycolysis -Cytosol 
-Protein disulfide-isomerase ER-60 -Metabolic process -Cytosol 
-RNA m5u methyltransferase -Methylation -Cytosol 
-Suppressor of actin (Sac) -Metabolic process -Membrane  
-Transducin beta-like -Regulation of transcription -Cytosol 
-Triosephosphate isomerase -Glycolysis -Cytosol 
-Ubiquitin protein ligase E3a -Protein ubiquitination -Cytosol 
-Ubiquitin-specific peptidase 30 (C19 family) -Protein ubiquitination -Cytosol 
-Uncharacterized protein, Smp_018790 (91,6% 
identity with PP2C-like domain-containing protein - 
S. haematobium) 
-Metabolic process -Cytosol 
Binding 
and 
Catalytic 
activity  
(16) 
-Alpha tubulin -Microtubule-based process -Cytoskeleton 
-ATP-dependent transporter (Transport) -Metabolic process -Membrane  
-Cell polarity protein -Metabolic process -Membrane  
-Elongation factor 1-alpha -Protein biosynthesis  -Cytosol 
-Enolase -Glycolysis -Cytosol 
-Galactokinase -Metabolic process -Cytosol 
-Glyceraldehyde-3-phosphate dehydrogenase -Glycolysis -Cytosol 
-Inosine-5'-monophosphate dehydrogenase -Protein biosynthesis  -Cytosol 
-Lysine tRNA ligase -Protein biosynthesis  -Cytosol 
-Ornithine aminotransferase -Metabolic process -Cytosol 
-Phosphoglycerate kinase -Glycolysis -Cytosol 
-Phosphopyruvate hydratase -Glycolysis -Cytosol 
-Protein kinase -Phosphorylation -Cytosol 
-Serine/threonine kinase -Phosphorylation -Cytosol 
-Serine/threonine phosphatase -Metabolic process and 
dephosphorylation 
-Cytosol 
-Tubulin beta chain -Microtubule-based process -Cytoskeleton 
*Numbers in brackets indicate the amount of proteins with those certain functions. 
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Table IV-4 (Continuation 2). Proteins identified by their MS/MS and categorized by their molecular 
function according to information obtained from GO database.  
Molecular 
function 
Protein name Biological Process Subcellular 
localization 
Transport 
(4) 
-Albumin -Transport -Extracellular 
matrix 
-Rab6-interacting protein 2 (ERC protein 1) - - 
Regulation 
of muscle 
contraction 
(4) 
-Tropomyosin-1 -Muscle contraction -Cytosol 
-Tropomyosin-2 -Muscle contraction -Cytosol 
-Troponin I - -Cytosol 
-Troponin T - -Cytosol 
Chaperone 
(3) 
-Major egg antigen (p40) - -Cytosol 
Motor (3) -Paramyosin -Muscle contraction -Cytoskeleton 
Structural 
(3) 
-Collagen alpha chain - - 
Unknown  
(2) 
-Twister (putative) - - 
-Uncharacterized protein, Smp_161260 (63,4% 
identity with SJCHGC05745 protein - S. 
japonicum) 
- - 
*Numbers in brackets indicate the amount of proteins with those certain functions. 
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5. Discussion 
Schistosomiasis is one of the most important infectious parasitic diseases, affecting 
millions of people worldwide, and representing a serious health problem [1, 2, 45]. 
Nowadays its control is based on PZQ, the only drug available for its treatment, which 
heavily relies on massive chemotherapy [3, 5, 7] However, the report of PZQ-
resistance cases by S. mansoni has become a serious problem that needs to be 
solved. Several reports from our group and others have suggested that resistance to 
Schistosoma infection can be acquired naturally or induced by drug [37, 46-48]. 
Besides experimental evidences, reports of treatment failure in Senegal and Egypt in 
isolates with reduced susceptibility to PZQ were obtained [49, 50] and further ex vivo 
experiments have confirmed the development of PZQ-resistance [37, 51-54]. Our 
group in particular has shown that resistance may be developed by drug pressure and 
as discussed in the Introduction section of this Chapter, we developed an important 
model that allows the laboratory study of PZQ-resistance in S. mansoni [37]. Taking 
advantage of our PZQ-resistant strain, the present study represents the first report of 
a S. mansoni PZQ-resistant strain proteomics analysis, comparing this strain with its 
isogenic counterpart susceptible strain, which is different only for the genetic 
determinants accounting for the PZQ-resistance phenotype. 
In the present study we identified 60 different proteins on S. mansoni proteome. All 
those proteins were present in worms not exposed to PZQ, but some of them 
disappeared when these worms were exposed to the same drug. This result could 
possibly indicate an effect of PZQ exposure on protein expression in resistant and 
susceptible strains. Although previous studies of Schistosoma proteome had been 
performed using protein extracts and Schistosoma species different from ours, some 
proteins, such as 14-3-3 protein, HSP-70, GAPDH, glutathione S-transferase 28 kDa, 
enolase, fructose-bisphosphate aldolase, actin, triose phosphate isomerase, calponin, 
elongation factor 1-α, phosphoglycerate kinase, phosphoglycerate mutase, myosin, 
and paramyosin were commonly identified [29, 36, 55-61]. In addition, some proteins 
that have already been tested as vaccine candidates, as glutathione S-transferase 28 
kDa [62, 63], triose phosphate isomerase [63, 64] and paramyosin [63] were also 
identified in the present study. Major egg antigen, troponin T, disulphide-isomerase 
ER-60 and actin, proteins that we also found, have already been clustered as 
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immunoreactive proteins in serum pools of infected or non-infected individuals from 
endemic area [36].  
Looking at the proteomes from both genders, in this survey, four proteins were only 
expressed in females from both strains, even under exposure to PZQ, namely, cytosol 
aminopeptidase, inosine-5'-monophosphate dehydrogenase (IMPDH), ubiquitin 
protein ligase E3a, and collagen alpha chain. Cytosol/leucine aminopeptidase 
catalyzes the hydrolysis of amino-acid residues from N-terminus of proteins and 
peptides [65], and it has already been assessed as a vaccine candidate against the 
infection of Fasciola hepatica [66]. This protein has previously been identified in S. 
mansoni eggs [67]. Regarding IMPDH, this protein is responsible for the rate-limiting 
step in guanine nucleotide biosynthesis [68], and it has previously been identified in 
Schistosoma genome and transcriptome [69]. E3 ligase enzyme catalyzes protein 
ubiquitination, which regulates various biological processes through covalent 
modification of proteins and transcription factors, and ubiquitin is the most important 
protein of this process [70, 71]. It has been suggested that ubiquitination is of interest 
in S. mansoni because this process could be a potential target for the design of new 
drugs [72], being ubiquitin protein ligase E3a a good target to be studied. In regard to 
collagen alpha chain, Yang and colleagues [73] described that silencing the expression 
of a type of collagen (type V collagen) significantly affects the spawning and egg 
hatching of S. japonicum, and it also affects the morphology of the worms [73]. 
Therefore, it would be very interesting evaluate the role of each of these proteins in 
PZQ-resistance, specially, collagen alpha chain, since it seems to occur morphological 
alterations in eggs and worms of S. mansoni PZQ-resistant strain [74]. Moreover, 
females of this species, the only gender in which those proteins were found in this 
work, are more tolerant to PZQ treatment than males [37]. 
Another large difference between the proteome of both genders was the expression of 
troponin I and serine/threonine-protein phosphatase. Those proteins were present in 
males independently of drug exposure, but in females they were only present in 
resistant females not exposed to PZQ. Troponin I belongs to the troponin complex that 
mediate Ca2+-regulation that governs the actin-activated myosin motor function in 
striated muscle contraction [75]. On the other side, protein kinases and phosphatases, 
as is the case of serine/threonine-protein phosphatase, are essential for normal 
functioning of signaling pathways, since it is well known that reversible phosphorylation 
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of proteins is a ubiquitous mechanism crucial for regulation of most cellular functions 
[76]. In S. mansoni, a phosphatase 2B (calcineurin) has been described as a 
heterodimer with a catalytic subunit and a regulatory subunit, which bind to Ca2+ 
increasing the phosphatase activity [77, 78]. Thus, protein phosphatases represent 
crucial molecules for the parasite and hence potential chemotherapeutic targets [79]. 
Those differences in proteomes of males and females of S. mansoni represents a 
remarkable finding that is in agreement with other works [59, 80], who have described 
a differential protein expression between males and females of Schistosoma spp.. 
However, these proteins are different from those described here, but it should be taken 
into account that those studies were performed with different species of Schistosoma 
[59, 80]. 
Regarding to resistant strain parasites, it is notable the finding of eight proteins 
exclusively expressed in those S. mansoni worms. From those eight proteins, 
dopamine transporter, twister (putative), ubiquitin-specific peptidase 30 (C19 family), 
and uncharacterized protein smp_162220 are not present in S. mansoni PZQ-exposed 
worms. However, galactokinase, ornithine aminotransferase, Rab6-interacting protein 
2 (ERC protein 1) and transducin beta-like remained after drug exposure. 
Dopamine/norepinephrine transporter (SmDAT) gene transcript, characterized in S. 
mansoni, is essential for the survival of the parasite as it causes muscular relaxation 
and a lengthening in the parasite, controlling movement [81]. Galactokinase catalyzes 
the second step of the Leloir pathway, a metabolic pathway found in most organisms 
for the catabolism of β-D-galactose to glucose 1-phosphate [82]. Galactokinase and 
hexokinase have similar enzymatic function on sugar phosphorylation [83], and 
characterization of schistosome hexokinase has been described as pertinent to 
understanding the metabolic response of S. mansoni cercariae to an increased 
glucose availability [84]. Ornithine aminotransferase was already identified in S. 
mansoni [85] and it has been characterized as playing a central role in ornithine 
biosynthesis [86]. It seems responsible for catalyzing the transfer of the delta-amino 
group of L-ornithine to 2-oxoglutarate, producing L-glutamate-gamma-semialdehyde, 
that in turn spontaneously cyclizes to pyrroline-5-carboxylate, and L-glutamate [87]. 
Rab6-interacting protein 2 is a member of a family of RIM-binding proteins, which are 
presynaptic active zone proteins that regulate neurotransmitter release [88]. Ubiquitin-
specific peptidase 30 (C19 family) belongs to a metabolic pathway that had previously 
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been associated to development of artemisinin and artesunate-resistance in 
Plasmodium chabaudi [89], which is a very interesting result. All those proteins 
specifically found in the resistant strain should be further studied to better understand 
if they could possibly have a fundamental role in PZQ-resistance development. 
Yet for the resistant strain parasites, there are three proteins, beta 1,3-
galactosyltransferase, cathepsin L, and receptor for activated Protein Kinase C (PKC) 
that are exclusive to resistant females, even after exposure to PZQ. Beta 1,3-
galactosyltransferase has previously been identified in Schistosoma genome and 
transcriptome [69]. Cathepsin L activity is believed to be involved in hemoglobin 
digestion by adult schistosomes [90], and Dalton and colleagues [90] suggested the 
involvement of cathepsin proteinases in several key functions render them as potential 
targets to novel antiparasitic chemotherapy and immunoprophylaxis. Putative PKC 
exists in kinomes of the blood flukes S. mansoni [91, 92], S. japonicum [93] and S. 
haematobium [94], and regulates movement, attachment, pairing, and egg release in 
S. mansoni, being considered a potential target for chemotherapeutic treatment 
against schistosomiasis [95]. These results really suggest a possible relationship 
between those proteins and PZQ-resistance in S. mansoni females, possibly being 
responsible for the exacerbated resistance demonstrated by those females in previous 
work performed by us [37]. 
Concerning the PZQ-susceptible strain, it should be noted eight proteins that only 
appeared in this strain. Phosphopyruvate hydratase (enolase), an important glycolytic 
enzyme that has the functions of activating the plasminogen, involving in the processes 
of infection and migration of parasites, reducing the immune function of the host as 
well as preventing parasites from the immune attack of the host [96], is the only protein 
from those eight proteins that continued to be expressed after PZQ exposure. This 
possibly suggests a relationship of this protein with the PZQ-susceptibility/resistance. 
However, more studies are necessary to investigate this hypothesis.  
All those results together represent an important finding for the study of PZQ-
resistance/susceptibility in S. mansoni, since they allow comparing directly the 
proteome under both conditions. We believe that the most promising candidates are 
proteins that appeared associated only to one of the strains, especially those with 
functions possibly related with the phenotypic alterations observed in the Chapter III 
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[74], or previously associated with resistance by others parasites to different drugs. 
These candidates require special attention in more studies, assessing for instance the 
level of protection induced by these proteins in animal models infected by both S. 
mansoni strains, as they may have some involvement on PZQ-resistance 
phenomenon.  
In conclusion, due to the increase of resistance by S. mansoni worms to the only drug 
available to treat schistosomiasis, it is imperative and urgent to study this phenomenon 
trying to understand what is involved in its occurrence. In this context, this work is 
extremely relevant since for the first time the proteome of a S. mansoni PZQ-resistant 
strain is characterized and compared to the proteome of S. mansoni PZQ-susceptible 
strain. The proteomics approach conducted here has lead to the identification of 
several proteins that were found to be characteristic of PZQ-resistant strain, and could 
putatively be involved in the PZQ-resistance phenomenon. Therefore, this is an 
innovative study that opens doors to PZQ-resistance surveys, contributing to discover 
a solution to PZQ-resistance problem as suggest new potential targets for new drugs. 
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1. Final discussion and future directions 
The emergence of PZQ-resistance in Schistosoma spp. populations is increasingly 
considered as a fact, and continued vigilance is recommended by health authorities [1, 
2]. Since EPs are involved in several chemotherapy failures [3, 4], in this work we 
tested their involvement in the PZQ-resistant phenotype in S. mansoni. With the 
assays performed, it was demonstrated that the Pgp-like transporter SmMDR2 has an 
involvement in PZQ-resistance in S. mansoni males, thus suggesting that MDR 
proteins are good targets to reverse the PZQ-resistant phenotype in S. mansoni males, 
deserving attention in future studies. Besides, the ex vivo assays performed showed 
that in the presence of an EPs inhibitor PZQ-susceptibility increased in males. 
Therefore, a combined therapy of PZQ and EPs inhibitors should be considered and 
studied in in vivo experiences since the administration of those inhibitors might 
increase worm susceptibility to PZQ. 
Regarding S. mansoni females, it was not possible to observe a role for the Pgp-like 
transporter SmMDR2 in PZQ-resistance. However, it was possible to determine that 
females are less susceptible to PZQ than males. Together these results strongly 
suggest that more than one pathway are involved in PZQ-resistance in S. mansoni 
worms. Therefore, it is of extreme importance to identify other mechanisms potentially 
involved in S. mansoni PZQ-resistance, in order to develop not only new drugs, but 
also new strategies for schistosomiasis control.  
Adaptation of a technique previously applied to bacteria and cell cultures [5], allowed 
us to evaluate efflux pump activity in a multicellular organism. This is an important 
technical development that can be used in further studies to assess EPs activity in 
more complex parasites, specially, in a drug-resistance scenario. 
A second section of this thesis aimed to compare the morphological characteristics of 
both PZQ-resistant and susceptible S. mansoni strains. With this analysis, it was 
possible to observe that when exposed to PZQ, resistant worms have less muscular 
contractions, less tegumental damage, higher viability and, after removal of the drug, 
a complete recover of motility. Those are important findings since any biological 
change can have repercussions in the pathology of the disease. This work makes it 
reasonable to hypothesize that the tegument of PZQ-resistant strain might have a 
different composition from susceptible one. It would be very interesting to explore this 
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difference, because knowing that the tegument can determine efficacy of the PZQ 
treatment, such studies could have great impact on schistosomiasis treatment [6-9]. 
Another important finding extracted from the morphological observation of the S. 
mansoni worms was the information that PZQ-resistant S. mansoni males and females 
are different, the latter being more resistant to PZQ treatment. Those findings reinforce 
the idea that the mechanisms involved in male and female PZQ-resistance may not 
always be the same, being necessary to study males and females in separate.  
Besides the adult worms, we also analyzed the eggs of both strains, before and after 
PZQ exposure. This led to an important finding, the occurrence of differences in egg 
morphology between those strains. While PZQ-susceptible females do not produce 
eggs under PZQ-exposure, PZQ-resistant females do produce. However, the PZQ-
resistant female eggs are smaller and have smaller spicules with different morphology 
(less saliente and less acute). These differences might have repercussions in what 
respects their tropism and it is even possibly that they reach the central nervous 
system, causing neuroschistosomiasis. If this hypothesis is correct, in regions where 
PZQ-resistant strain are circulating, changes in pathology and in disease transmission 
could occur. It is urgent to explore this hypothesis, determining not only whether 
differences in the tropism of PZQ-resistant eggs do occur, but also other possible 
differences occurring in this same life stage. 
Proteomics is an important means to characterize species or strains [10], and in 
combination with classical biochemical purification methods, can provide information 
on expression and localization of proteins [11]. Here, we characterized for the first time 
the proteome of a PZQ-resistant S. mansoni strain and the respective isogenic 
susceptible strain, a very important step towards understanding PZQ-resistance. This 
allowed us to identify proteins possibly associated with PZQ-resistance. These are 
proteins that were found to be differentially expressed between the strains. Since these 
proteins may be related with the PZQ-resistance phenomenon their functional 
characterization should pursue in future studies aimed at identifying new drug targets 
for schistosomiasis control. The identification of the proteins putatively associated with 
PZQ-resistance in S. mansoni permits also to investigate the possibility of developing 
a diagnosis test to distinguish patients carrying PZQ-resistant strains from those with 
PZQ-susceptible S. mansoni. The development of such a test would constitute a major 
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step towards schistosomiasis control as it would render possible to adjust drug 
administration in order to increase treatment efficacy (perhaps even by combining PZQ 
with EPs inhibitors as suggested previously). Another advantage of being able to 
detect PZQ-resistant infections at an early phase is that it would make clinical staff 
more aware of the possible differences in disease pathology, preventing some 
complications (for example, the early detection of neuroschistosomiasis would facilitate 
treatment).  
The proteome analysis made it also possible to identify proteins that were present only 
in females, being these good targets to identify the mechanisms underlying the 
decreased PZQ-susceptibility of females, when compared to males. Furthermore, 
some of these proteins may constitute targets, for schistosomiasis control. They 
should, therefore, be object of further analysis. In this context, the development and 
use of other techniques, such as genetic manipulation methods, will be crucial to 
further unravel the intriguing biology of schistosomes and their complex interaction with 
the host [11]. 
In summary, this thesis presents an innovative study, with important and relevant 
discoveries for public health. This work opens doors to other PZQ-resistance studies, 
and could possibly represent a basis to find a solution to the PZQ-resistance problem 
in a disease that affects millions of people worldwide.  
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